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Rheumatoid arthritis (RA) is an auto-immune disorder characterized by chronic inflam-
mation of synovial joints. Although the precise etiology of the disease has not yet been 
established, it is known that both environmental and genetic factors play a pivotal role in 
development of the disease. In the current thesis, studies to unravel the genetic basis of 
RA and the putative functional consequences of these genetic variances are described. 
Rheumatoid arthritis
RA is a chronic inflammatory disease characterized by persistent synovitis and destruction 
of synovial joints, leading to severe disability, decreased quality of life and premature mor-
tality. In industrialized countries approximately 0.5-1.0% of the adult population is affected 
by the disease, with a dominance in females and elderly individuals. The disease reveals 
itself by joint swelling and joint tenderness, in which the small joints of the hands and feet 
are most commonly affected1. 
The definition of RA is phenotypic and is defined by use of classification criteria. These 
criteria were developed on a consensus procedure by clinical experts and resulted in the 
ACR 1987 criteria2. 
A score of ≥6 is the cutpoint for rheumatoid arthritis. Patients
can also be classif ied as having rheumatoid arthritis if they
have: 1) erosive disease typical for rheumatoid arthritis, 2)





1-3 small joints (large joints not counted)
4-10 small joints (large joints not counted)
>10 joints (at least one small joint)
•Serology
Negative RF and negative ACPA
Low-positive RF or low-positive ACPA
High-positive RF or high-positive ACPA
•Acute-phase reactants
Normal CRP and normal ESR


















•Morning stiffness (at least 1h)
•Arthritis of three or more joint areas






Four of seven criteria must be present. Criteria 1-4 must have
been present for at least 6 weeks.
Figure 1. ACR 1987 criteria and ACR/EULAR 2010 criteria. Classification criteria for rheumatoid ar-
thritis. ACR = American College of Rheumatology. EULAR = European League Against Rheumatism. 
RF = rheumatoid factor. ACPA = Anti Citrullinated Peptide Antibodies. CRP = C-reactive protein. ESR 





These criteria are well accepted for disease definition, but have proven to be of limited 
value in defining the earliest forms of RA. Therefore, recently, a new set of criteria has been 
developed (Figure 1)3. 
The mainstay of treatment in RA, are the Disease Modifying Anti Rheumatic Drugs 
(DMARDs), which are a heterogeneous collection of therapeutic agents of which the mech-
anisms of action are, largely, not well understood. When arthritis stays uncontrolled de-
spite these agents, or when toxic effects arise upon administration of these drugs, biologic 
agents, such as tumor necrosis factor inhibitors can be used and have proven to be highly 
effective1.
Pathophysiology
The inflamed synovial tissue is expanded by recruitment and retention of inflammatory 
cells, like macrophages, T- and B-cells. This leads to the formation of villous projections 
and the generation of pannus tissue, which is a feature seen in joints of RA patients. This 
pannus tissue results from proliferating synovium and is thought to mediate tissue destruc-
tion. Chronic synovitis is maintained by interaction of native and recruited inflammatory 
cells with subsequent establishment of cytokine networks. The combination of chronic 
inflammation and formation of pannus tissue will eventually lead to joint space narrowing 
and joint erosions4,5. 
RA is considered to have an auto-immune nature, because of the presence of autoantibod-
ies and autoreactive T-cells in peripheral blood and synovial fluid. These autoantibodies are 
already present in the earliest stages of disease and can precede disease onset by several 
years4. 
The classic autoantibody in RA is rheumatoid factor (RF) and was first described in 1940 by 
Erik Waaler. This antibody is directed to the Fc portion of IgG, which is important for com-
plement fixation and interaction with Fc receptors. The etiology of RF and its precise role in 
the pathogenesis of RA is still incompletely understood. RF is not unique for RA and is also 
present in other autoimmune diseases, infectious diseases and in healthy elderly individu-
als. The sensitivity varies between 60 and 70% and the specificity between 50 and 90%6. 
An additional type of autoantibody is directed against citrullinated peptides and is called 
Anti Citrullinated Peptide Antibody (ACPA). Citrullination is the post translational modifica-
tion of protein-bound arginine into the non-standard amino acid citrulline (Figure 2). This 
process is mediated by an enzyme called peptidylarginine deiminase (PAD)7,8. The role of 
citrullination remains to be determined, however, it is known that the process of citrullina-
tion typically occurs in apoptotic cells. This results in a small change of molecular mass 
and loss of a positive charge. It has been proposed that this process prepares intracellular 




Although the presence of these antibodies has first been described in the early 1970’s, it 
was not until the last decade that it became clear that  these antibodies are highly predic-
tive and specific for RA. The observations that these antibodies precede disease onset and 
that citrullinated antigens can be found in the inflamed joint, lead to the hypothesis that 
these antibodies play a role in the pathophysiology of RA11,12. 
Risk factors
Environmental factors
The major environmental risk factor for RA is smoking, which doubles the risk of devel-
oping the disease. This risk factor, however, is restricted to the ACPA positive disease 
subset13. Other factors that might influence the development of the disease have been 
proposed, but supporting evidence is weak and should be investigated more thoroughly. 
Genetic factors
The first evidence for a genetic component in the susceptibility of RA came from twin 
and family studies. These studies showed that among siblings, the prevalence of RA was 
increased to 2-4% and that the concordance rate for monozygotic twins was 12-15%, as 
compared to 2-4% for dizygotic twins14,15. Additionally, the heritability of RA, which esti-
mates the extent to which variation in liability to disease in a population can be explained 
by genetic variation, was calculated to be about 50%16. These studies demonstrate that 
genetic factors have a substantial impact on RA susceptibility.
The most important genetic risk factor was first described over 30 years ago and is con-
fined to the human leukocyte antigen (HLA) locus17. Studies have shown that several HLA-
DRB1 alleles are associated with the disease and that different alleles associate in differ-
ent ethnic populations18,19. Interestingly, the association is confined to the ACPA positive 
Figure 2. Citrullination of an aminoacid. Posttranslational modification of arginine into citrulline, me-





subset of the disease20.
The HLA-DRB1 alleles encode the variable region of the HLA class II molecule. This vari-
able region constitutes the binding groove for the peptide that is presented by the HLA 
molecule to T-cells. The product of the associated HLA-DRB1 alleles appears to share the 
same amino acid sequence at position 70-74 in the third hypervariable region of the HLA 
class II molecule.  Therefore, the collection of different associated alleles are called the 
Shared Epitope (SE) alleles21,22. The SE hypothesis postulates that the SE motif is directly 
involved in RA pathogenesis by allowing presentation of certain (arthritogenic) peptides to 
T-cells23. To date, no specific peptide that is presented in this binding groove and subse-
quently activates autoreactive T-cells has been identified. 
The total genetic contribution of the SE alleles to RA has been quantified in twin studies 
and is estimated to be 50-60% of the genetic contribution16. Therefore the HLA locus is 
thus far the most powerful genetic factor and accounts for approximately 30% of the ge-
netic burden to RA25. 
It required almost 30 years before evidence of genetic associations outside the HLA lo-
cus were convincingly demonstrated by the discovery of PADI4 and PTPN22. PADI4 was 
discovered in a Japanese RA population by fine mapping of a linkage region on chromo-
some 1p3626.  Interestingly, this gene encodes the PAD enzyme, which is needed for the 
posttranslational modification of arginine into the, by ACPAs recognized, citrulline8. The 
association has been convincingly replicated in other Asian populations, but could not be 
established the in Caucasian population27,28. 
The discovery of PADI4 was followed by the identification of the genetic association with 
PTPN22. This gene was initially identified in a multi-tiered, case control study of putative 
functional single nucleotide polymorphisms (SNPs) in a Caucasian population from North 
America. The identified risk allele encodes an amino acid change, which is thought to al-
ter the proteins normal function29. Well powered studies have successfully replicated the 
association and it is thought of as the most reproducible genetic association outside the 
HLA region30. The associated variant shows a decreasing frequency going north to south in 
European populations, with a minor allele frequency of approximately 15% in Scandinavia 
to 2.5% in the Italian population29. The risk allele is virtually absent in Asian populations 
and attempts of identifying additional PTPN22 alleles in this population have not been 
successful31. Contrasting, in the case of PADI4, the risk allele is present in the Caucasian 
population, but has not proven to be associated with the disease. 
After 2004 the identification of new genetic risk factors accelerated, due to advances in 
genotyping technology, available at reasonable costs. By candidate gene approach the 
CTLA4 gene was identified, followed by the identification of the C5/TRAF region32,33. This 
region was detected concurrently in a genome wide association study (GWAS)34. Linkage 
data led to the identification of STAT4 as a genetic risk loci35. Large GWAS in ACPA positive 
individuals allowed the identification of new genetic risk factors to take enormous steps 




of which the most significant finding is located near the CD40 gene36. Currently, over 100 
genetic loci are considered as established genetic risk factors for RA, all with relatively 
weak effects with moderate ORs37. 
Aim and outline of this thesis
The aim of this thesis is to get more insight into the genetic contribution of loci located 
outside the HLA region to RA susceptibility and the functional role the associated variants 
play in disease pathology.
In recent years many genetic risk loci, located outside the HLA region, have been identified. 
Some of these loci represent true associations, while others will prove to be false positive 
findings. In chapter 2 and chapter 3 replication studies to identify the true genetic contri-
bution of STAT4, IL2/IL21, CTLA4 and IL2RA to RA susceptibility was investigated in the 
Leiden RA population. Subsequently, to establish the true genetic effect of these loci, a 
meta-analysis combining all previously published data was performed.
In Chapter 4 we investigated the genetic contribution of the, then known, non HLA genes 
in a subset of North American Natives, that confer a higher risk to develop RA. Subse-
quently, we investigated whether an interaction between the genes was present and would 
confer a higher risk obtaining the disease.
To identify additional genetic risk factors for RA, a candidate gene study to investigate the 
genetic contribution of the VTCN1 region to RA susceptibility was performed in chapter 
5. Based on previously published genetic association data of this region with juvenile idio-
pathic arthritis and indications in mouse models, we hypothesized that the VTCN1 region 
might play a role in the development of RA. 
In chapter 6 the genetic contribution of the PTGES gene was explored in relation to dis-
ease susceptibility and various disease outcomes, like gender, DAS28 and age of onset of 
RA. Gene expression was investigated in RA synovium and related to genotype.
Additionally, a candidate gene study on the genetic susceptibility of the C1Q region with 
RA was investigated in chapter 7. We hypothesized that C1Q, which plays a pivotal role 
in activation of the classical pathway of the complement system, is a genetic risk factor 
for RA susceptibility. Subsequently, gene expression profiles and C1q serum levels were 
investigated in relation to genotypes. 
Subsequently, in Chapter 8, the role of the complement system to activate autoantibodies 
was summarized in a review that discusses the different pathways of activation.
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Recent advances have led to novel identification of genetic polymorphisms that are associ-
ated with susceptibility to rheumatoid arthritis (RA). Currently, 5 loci (HLA, PTPN22, TRAF1/
C5, TNFAIP3, and STAT4) have been consistently reported, whereas others have been 
observed less systematically. The aim of the present study was to independently replicate 
3 recently described RA susceptibility loci, STAT4, IL2/ IL21, and CTLA4, in a large Dutch 
case-control cohort, and to perform a meta-analysis of all published studies to date and 
investigate the relevance of the findings in clinically well-defined subgroups of RA patients 
with or without autoantibodies.
Methods
The STAT4, IL2/IL21, and CTLA4 gene polymorphisms (rs7574865, rs6822844, and 
rs3087243, respectively) were genotyped in 877 RA patients and 866 healthy individuals. 
A meta-analysis of all published studies of disease association with these polymorphisms 
was performed using the Mantel-Haenszel fixed-effects method.
Results
An association of STAT4, IL2/IL21, and CTLA4 with RA was detected in Dutch patients 
(odds ratio [OR] 1.19 [P = 0.031], OR 0.84 [P = 0.051], and OR 0.87 [P = 0.041], respective-
ly). Results from the meta-analysis confirmed an association of all 3 polymorphisms with 
RA in Caucasians (OR 1.24 [P = 1.66 x 10-11], OR 0.78 [P = 5.6 x 10-5], and OR 0.91[P = 1.8 
x 10-3], respectively). The meta-analysis also revealed that STAT4 predisposed to disease 
development equally in patients with autoantibodies and those without autoantibodies, 
and that CTLA4 enhanced the development of anti-citrullinated protein antibody (ACPA)-
positive RA as compared with ACPA-negative RA.
Conclusion
Our results replicate and firmly establish the association of STAT4 and CTLA4 with RA 
and provide highly suggestive evidence for IL2/IL21 loci as a risk factor for RA. Given the 
strong statistical power of our meta-analysis to confirm a true-positive association, these 





Confirmation of association of STAT4, IL2/IL21 and CTLA4
InTroducTIon
Rheumatoid arthritis (RA) is a common auto-immune disease with unknown etiology. 
Nonetheless, it is known that both genetic and environmental factors play a role in the 
pathogenesis of the disease. The strongest known genetic association with RA is with par-
ticular alleles of the HLA locus1. In recent years, continuing advances in genotyping tech-
niques have led to discovery of a large number of potential genetic associations outside 
this region2-4. Some of these newly identified susceptibility loci represent true associations, 
whereas others still remain to be conclusively investigated.
Followup replication studies in different populations are needed to resolve this issue. How-
ever, although some followup studies have shown robust associations, others have yielded 
encouraging, but inconsistent, results. This could be due to insufficient power to detect 
modest effects in some of these studies. To overcome this limitation, data from previously 
published studies can be systematically evaluated by a meta-analysis. Furthermore, since 
RA is a heterogeneous disease and data indicate that different risk factors predispose to 
autoantibody-positive disease as compared with autoantibody-negative disease5, further 
investigation in these disease subsets remains to be performed in large data sets. In the 
present study, 3 previously described susceptibility loci in patients with RA, i.e., rs7574865 
(for signal transducer and activator of transcription 4 [STAT4]), rs6822844 (for interleukin-2/
interleukin-21 [IL2/IL21]), and rs3087243 (for cytotoxic T lymphocyte- associated antigen 
4 [CTLA4]), were investigated for association with the disease and for association with 
autoantibody status.
The association of STAT4 with RA was first described in 2007, followed by a vast number 
of rep-lication studies in both Caucasian and East Asian populations, all of which yielded 
results that were consistent across the studies3,6-11. In contrast, the second polymorphism 
in this study, namely, rs6822844 in the IL2/IL21 region, has only been described in one 
study thus far, indicating that further replication is needed4. The third variant that we aimed 
to investigate maps to the CTLA4 region. Various replication studies have shown encour-
aging, yet inconsistent, results for this locus12-17. Plenge et al provided evidence that the 
differences between studies could be due to insufficient power in some of the studies15.
Thus, the aim of our study was to replicate 3 previously described risk factors for RA and 
further study their association by a meta-analysis. Additionally, we examined whether the 




A total of 877 RA patients whose diagnosis met the American College of Rheumatology 




cruited in 1994 from hospitals in the western part of The Netherlands, of whom 602 pa-
tients were from 2 independent cohorts of patients with early arthritis, the EAC and BeSt 
cohorts, and 275 were from the outpatient clinic of the Leiden University Medical Center. 
For both early arthritis cohorts, anti-citrullinated protein antibody (ACPA) status and rheu-
matoid factor (RF) status were obtained. For the patients from the outpatient clinic, only 
the RF status was obtained. Patients’ characteristics have been described previously19. 
As healthy controls, 866 subjects were randomly selected from the Immunogenetics and 
Transplantation Immunology section of Leiden University Medical Center. All patients and 
controls gave their informed consent to participate in the study, and the study was ap-
proved by the local ethics committee of the participating hospitals.
Genotyping methods
Genotyping of STAT4 rs7574865, IL2/IL21 rs6822844, and CTLA4 rs3087243 was per-
formed using MassArray matrix-assisted laser desorption ionization-time-of-flight mass 
spectrometry, according to the protocols recommended by the manufacturer (Sequenom, 
San Diego, CA). SpectroCaller software, which was supplied by the same manufacturer, 
was used to automatically identify, i.e., call, the genotypes. Each 384-well plate consisted 
of 8 positive controls and 8 negative controls, all of which were indeed shown to be positive 
or negative. Clusters were evaluated and all doubtful calls were checked; after manually 
evaluating the spectra of each cluster, the genotypes were accepted, recalled, or rejected. 
At least 10% of the genotypes were assessed in duplicate, with an error rate of <1%.
Statistical analysis 
Allele distribution was analyzed for association with RA using a chi-square test with 1 
degree of freedom. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were cal-
culated using the Statcalc module of Epi Info software (Centers for Disease Control and 
Prevention, Atlanta, GA). P values less than 0.05 were considered significant. Genotype 
frequencies in cases and controls did not deviate from Hardy-Weinberg equilibrium at a 
significance level of P < 0.05. A meta-analysis of published reports describing disease 
associations with STAT4, IL2/IL21, and CTLA4 was performed using the Mantel-Haenszel 
method of combining ORs. Reports published up to July 31, 2008 were included in the 
analysis. Heterogeneity of the ORs across sample sets was analyzed using the Breslow-
Day test. Since no significant heterogeneity was observed among the studies, the ORs 
and 95% Cls were calculated using a fixed-effects model, and P values less than 0.05 
were considered significant. (Genotype frequencies are available upon request from the 
corresponding author.) The meta-analyses had >80% power to detect allele associations 
both for association with
RA and for association with autoantibody status, at ORs of <1.18 (at a significance level 
of P < 0.05) for all 3 polymorphisms, except for the association of the IL2/IL21 locus with 
autoantibody status, in which the meta-analysis had 67% power to detect an OR of 1.20 




Confirmation of association of STAT4, IL2/IL21 and CTLA4
resulTs
Replication of STAT4, IL2/IL21, and CTLA4 loci in an independent Dutch cohort 
The polymorphisms STAT4 rs7574865, IL2/IL21 rs6822844, and CTLA4 rs3087243 were 
genotyped in 877 RA patients and 866 healthy controls. Both STAT4 and CTLA4 showed 
an association with RA in the Dutch cohort, while a clear trend toward association was 
observed for the IL2/IL21 locus (Table 1). The results had the same direction of association 
as has been reported in previous studies3,4,6,9-12,14,15,17.
Table 1. Results of association and stratification analysis of STAT4 rs7574865, IL2/IL21 
rs6822844, and CTLA4 rs3087243 in a Dutch cohort*
STAT4 rs7574865 IL2/IL21 rs6822844 CTLA4 rs3087243
Allele Allele Allele
G T MAF OR (95% CI) P G T MAF OR (95% CI) P A G MAF OR (95% CI) P
RA
Cases 1,276 432 0.25
1.19  
(1.01-1.40) 
0.031 1,469 285 0.16
0.84  
(0.70-1.0) 




Controls 1,348 384 0.22 1,407 325 0.19 785 941 0.45
RF status
RF+ 711 239 0.25
1.18  
(0.98-1.43) 
0.080 811 163 0.17
0.87  
(0.70-1.08) 




RF- 362 116 0.24
1.12  
(0.88-1.44) 
0.332 422 78 0.16
0.80 
(0.61-1.06) 
















ACPA+ 478 158 0.25
1.16  
(0.93-1.44) 
0.170 552 102 0.16
0.80 
 (0.62-1.03) 




ACPA- 325 111 0.25
1.20  
(0.93-1.54) 
0.144 380 76 0.17
0.87 
 (0.65-1.15) 
















* Values for alleles G, T, and A are the allele frequency. MAF = minor allele frequency; OR = 
odds ratio; 95% CI = 95% confidence interval;




Stratification by autoantibody status
For a better understanding of disease etiology, we investigated whether the associations 
were restricted to a specific subset of disease, defined by either ACPA positivity or RF pos-
itivity. In these subsets, no differential association could be observed for either the STAT4 
polymorphism or the IL2/IL21 polymorphism (Table 1). The CTLA4 polymorphism, however, 
did show a significant association with ACPA-positive RA in patients as compared with 
healthy controls (OR 0.80, 95% CI 0.66-0.96, P = 0.015), but showed no association with 
ACPA- negative RA in patients as compared with healthy controls (OR 0.90, 95% CI 0.70-
1.12, P = 0.325). Furthermore, an increase in frequency of the G allele was observed in 
patients with ACPA-positive RA (60%) as compared with patients with ACPA-negative RA 
(57%), but the difference was not significant.
Meta-analysis of STAT4, IL2/IL21, and CTLA4 loci.
Association with RA overall.
To systematically assess the contribution of the 3 studied polymorphisms in RA, a meta-
analysis of all published studies to date was performed. This analysis provided an overall 
OR for the widely and consistently replicated STAT4 locus in the Caucasian population (OR 
1.24, 95% CI 1.17-1.33, P = 1.66 X 10-11) (Table 2). Evaluation of both studies dealing with 
IL2/IL21 provided additional evidence of an association of IL2/IL21 with RA in Caucasians 
(OR 0.78, 95% CI 0.69-0.88, P = 5.6 X 10-5). Examination of the 6 previously published 
studies on rs3087243 in CTLA4 confirmed an overall association of this region with RA in 
Caucasians (OR 0.91, 95% CI 0.85-0.96, P = 1.8 X 10-3) (Table 2).
Association with RA stratified by autoantibody status. 
Results from our meta-analysis indicated that STAT4 was associated with both autoanti-
body-positive and autoantibody-negative disease in the Caucasian population (OR 1.00, 
95% CI 0.89-1.14, P = 0.97) (Table 3). Moreover, IL2/IL21 showed a significant association 
with RF-positive disease in Caucasian patients as compared with healthy controls (OR 
0.78, 95% CI 0.68-0.90, P = 6.9 X 10-4), but IL2/IL21 showed no significant association 
with RF-negative disease in Caucasian patients as compared with controls (OR 0.82, 95% 
CI 0.66-1.03, P = 0.083). However, the effect sizes of both associations were of the same 
extent. Furthermore, the effect size of RF-positive disease compared with RF-negative 
disease was limited, indicating an association of IL2/IL21 in both disease subsets (OR 
1.02, 95% CI 0.81-1.29, P = 0.86) (Table 3). Interestingly, in the meta-analysis, CTLA4 in the 
Caucasian population was found to predispose to ACPA-positive disease only, and not to 
ACPA-negative disease (OR 0.86, 95% CI 0.78-0.96, P = 4.7 X 10-3) (Table 3).
dIscussIon
In the present study, 2 genetic risk factors for RA were replicated in an independent Dutch 
population, with a third genetic risk factor showing a clear trend toward association. All 3 




Confirmation of association of STAT4, IL2/IL21 and CTLA4
phisms have been described in several autoimmune diseases, varying from type 1 diabetes 
to systemic lupus erythematosus3,4, which further emphasizes their role in autoimmunity. 
In RA, previous studies have suggested that genetic risk factors predispose to specific 
subsets of the disease, characterized by autoantibody status. For example, both the HLA 
shared epitope and PTPN22 loci have been shown to be associated with a clear predis-
position to ACPA-positive disease only. At a biologic level, classifying these genetic risk 
factors will ultimately enable a better understanding of the disease processes involved. 
Although STAT4, IL2/IL21, and CTLA4 have been found in association with ACPA-positive 
disease20, they have not been investigated extensively in autoantibody-negative patients.
In this study, we did not observe a difference in effect size between the autoantibody strata 
for either STAT4 or IL2/IL21. Our results are consistent with recent findings for STAT4. 
Zhernakova and colleagues4 have shown an association of IL2/IL21 in RF-positive patients 
as compared with controls, but no conclusive difference could be established between the 
2 subgroups. In support of these findings, our combined data sets also indicated that IL2/
IL21 predisposes individuals to both autoantibody-positive and autoantibody negative dis-
ease. However, additional replication in independent cohorts will still be necessary to tease 
apart the precise role of IL2/IL21 in these disease subsets. The results from several studies 
previously suggested that CTLA4 is associated with RA in an autoantibody-dependent 
manner. However, we provided, for the first time, conclusive evidence that CTLA4 is as-
sociated with ACPA-positive RA, but not with ACPA-negative RA.
conclusIon
In conclusion, this study provides independent replication of an association of STAT4, IL2/
IL21, and CTLA4 with RA, as well as substantial evidence of the involvement of CTLA4 in 
ACPA-positive disease only, as compared with the involvement of STAT4 and IL2/ IL21, 
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Rheumatoid arthritis (RA) is an autoimmune disease with a worldwide prevalence of ap-
proximately 1%. The aetiology of RA is largely unknown, but it is thought that both genetic 
and environmental factors play a role in the pathogenesis of the disease. Genome-wide 
association studies (GWAS) and candidate gene approaches have led to the association 
of a number of genetic susceptibility loci1-7. The Wellcome Trust case-control consortium 
(WTCCC), the first GWAS in RA, identified a number of loci reaching genome-wide signifi-
cance including the HLA region and the PTPN22 gene5. To identify new genetic risk factors, 
Thomson et al investigated whether tier 2 single nucleotide polymorphisms (SNPs) (p = 
1 x10-5-1 x10-7) in the WTCCC-GWAS showed an association with RA in an independent 
validation study of 5063 patients and 3849 healthy controls8. Of the nine loci investigated, 
a significant association was identified with rs6920220 in the TNFAIP3-OLIG3 region (odds 
ratio (OR) 1.23, 95% confidence interval (CI) 1.15 to 1.33, p=1.1x10-8). The association of 
RA with this region was independently identified by Plenge and co-workers2, and a recent 
meta-analysis of GWAS data from three independent case-control populations of Euro-
pean descent confirmed these results3.
To further investigate these tier 2 SNPs, the control group of the validation study was en-
larged from 3849 to 11 487 individuals by including non-RA disease groups consisting of 
bipolar disorder, type 2 diabetes, hypertension and coronary artery disease9. In addition 
to an association with rs6920220, other statistically significant SNPs surfaced, located in 
MMEL1, IL2RA and IL2RB. Furthermore, investigation of 49 tier 3 loci (p = 1 x10-4-1 x10-
5) from the original WTCCC-GWAS identified significant RA-associated SNPs located in 
PRKCQ and KIF5A.8 Three of these regions, encoding MMEL1, KIF5A and PRKCQ, were 
also identified in a large independent study of RA samples of European descent3, suggest-
ing that these regions harbour true RA susceptibility loci.
In the present study we addressed the contribution of the two interleukin 2 (IL2) pathway 
SNPs - specifically, rs743777 located in IL2RB and rs2104286 in IL2RA - to the risk of RA in 
an independent Dutch case-control study. This is of relevance not only because additional 
replication would strengthen the putative contribution of IL2 receptor-positive cells to RA, 
but also because only a trend towards association for the IL2RA SNP was observed after 
correction for multiple testing using the Bonferroni method (p<0.005).
MeTHods
A total of 616 Dutch patients and 545 healthy ethnically- and geographically-matched con-




Replication studie of IL2RA and IL2RB
resulTs
In this study a significant association with RA was observed for both rs743777 and 
rs2104286 (OR 1.26, 95% CI 1.06 to 1.50, p = 0.009 and OR 0.81, 95% CI 0.67 to 0.98, 
p = 0.026 respectively; table 1). Combining the data from our study with the UK data 
strengthened the evidence for an association (rs743444: OR 1.12, 95% CI 1.06 to 1.18, p 
= 8.6x10-6; rs2104286: OR 0.92, 95% CI 0.87 to 0.97, p=1.2x10-3; table 1). To bypass the 
phenomenon of the ‘‘winner’s curse’’, in which effect sizes are often overestimated in the 
original study,13 we opted to analyse the data without the original WTCCC data to provide 
an estimate of the most likely effect size.
 
conclusIon
In conclusion, this study provides additional evidence for the association of IL2RB and IL-
2RA with RA by independent replication in a Dutch population, underlining the importance 
of the IL2 pathway in RA. Recently, the IL2RA region was also found to be associated with 
other autoimmune diseases11,12 - specifically, multiple sclerosis and type 1 diabetes - which 
suggests a possible common functional pathway.
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Allele frequency data of RA cases versus controls was compared using a fixed effects (Mantel-
Haenszel) meta-analysis. No significant heterogeneity or deviation from Hardy-Weinberg (HW) equi-
librium was observed among the studies.       
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Most of the genetic risk for rheumatoid arthritis (RA) is conferred by ‘shared epitope’ (SE), 
encoding alleles of HLA-DRB1. Specific North American Native (NAN) populations have RA 
prevalence rates of 2-5%, representing some of the highest rates estimated worldwide. As 
many NAN populations also demonstrate a high background frequency of SE, we sought 
to determine whether other genetic factors contribute to disease risk in this predisposed 
population.
Methods
RA patients (n = 333) and controls (n = 490) from the Cree/Ojibway NAN population in 
Central Canada were HLA-DRB1 typed and tested for 21 single-nucleotide polymorphisms 
(SNPs) that have previously been associated with RA, including PTPN22, TRAF1-C5, 
CTLA4, PADI4, STAT4, FCRL3, CCL21, MMEL1-TNFRSF14, CDK6, PRKCQ, KIF5A-PIP-
4K2C, IL2RB, TNFAIP3, IL10-1082G/A and REL.
Results
Our findings indicate that SE is prevalent and represents a major genetic risk factor for 
RA in this population (82% cases versus 68% controls, odds ratio = 2.2, 95% confidence 
interval 1.6-3.1, P< 0.001). We also demonstrate that in the presence of SE, the minor al-
lele of MMEL1-TNFRSF14 significantly reduces RA risk in a dominant manner, whereas 
TRAF1-C5 increases the risk.
Conclusion
These findings point to the importance of non-HLA genes in determining RA risk in a popu-




Non-HLA genes modulate the risk of RA
InTroducTIon
Rheumatoid arthritis (RA) affects populations worldwide, with prevalence rates of 0.5-1% 
typically estimated in European and United States populations, and lower rates in African, 
Chinese and Japanese populations1. However, several North American Native (NAN) popu-
lations have substantially higher prevalence rates, estimated as high as 5.3% in the Pima of 
Arizona and 2.4% in the Tlingit of Alaska2-4. The shared epitope (SE) hypothesis postulates 
that RA predisposing alleles of the HLA-DRB1 locus encode for a positively charged QK(R)
RAA sequence in position 70-74 in the third hypervariable region of the molecule5. In most 
populations, the SE sequence is found in HLA-DRB1*04 alleles. In NAN populations, SE-
bearing alleles are primarily HLA-DRB1*1402 and *04046-10. High background population 
frequencies of the SE may, in part, explain the higher prevalence rates of RA in NAN popu-
lations, compared with other populations. For example, frequencies of the SE vary from 28 
to 38% in United States and United Kingdom Caucasians, but frequencies as high as 60 
to 95% have been reported in several NAN populations, where they have been studied8,11.
In European populations, the contribution of HLA to genetic risk of RA has been estimated 
at 37%12. The availability of the human genome sequence, high through-put single-nucle-
otide polymorphisms (SNP) technologies and large cohorts of RA patients has allowed the 
identification of associations with 20-30 new non-HLA gene regions, using both candidate 
gene and genome wide association scans (GWAS). These have included PTPN22, CTLA4, 
TRAF1-C5, STAT4, TNFAIP3, CD40, MMEL1-TNFRSF14 and REL13,14. Interestingly, these 
studies have suggested ethnic differences in the patterns of genetic susceptibility, neces-
sitating confirmation of associations in different populations15-17. Examples are a PTPN22-
R620W polymorphism which is strongly associated with RA and other autoimmune dis-
eases in Caucasian populations, but is absent in Orientals, and an association with PADI4 
SNP found in Japanese populations which is not detected in most Caucasian populations, 
despite the presence of these gene polymorphisms15-20. Our own studies of the Cree/Ojib-
way population in Central Canada have suggested a 2-3% prevalence rate of diagnosed 
RA, and a 60-70% frequency of SE alleles in the background population7,8,21. We sought 
to determine additional non-HLA genes that may contribute to the high frequency of RA 
detected in this population. We, therefore, genotyped NAN RA patients and controls for a 
spectrum of SNPs that were shown to be disease associated, using candidate gene and 
GWAS approaches in other populations. Our results indicate that several of these SNPs 
may contribute to disease risk in this population, with an SNP in the MMEL1-TNFRSF14 






We recruited RA patients and controls of Cree, Ojibway or Ojicree ethnic background. To 
be included in the study, all patients and controls had at least three of four grandparents of 
this ethnic background by self-report. A total of 338 RA patients were recruited from rheu-
matology clinics in urban areas of Central Canada, Winnipeg and Saskatoon, as well as 
rural areas, Norway House and St Theresa Point, Manitoba. A total of 516 controls from the 
same geographic areas were recruited by one of three methods: an accompanying spouse 
of an RA proband, a participant in a Health Fair, or through random sampling of the study 
communities. The latter approach accounted for most of the controls recruited from the 
rural locations. All controls had no history of RA or other autoimmune diseases.
The study protocol was approved by the Research Ethics Board of the University of Mani-
toba and by the Tribal Band Councils of the study communities. All study subjects gave 
informed consent after having the study details explained in their language of choice.
HLA-DRB1 testing
HLA-DRB1 testing was performed by polymerase chain reaction, using sequence-specific 
oligonucleotide primers and sequence-based typing as previously described8. The follow-
ing DRB1 alleles were included as SE-bearing alleles: DRB1*0101, 0102, 0401, 0404, 0405, 
0408, 0410, 1001 and 1402. Other SE-bearing alleles were not found in this population.
SNP testing in non-HLA genes
The complete list of SNP evaluated in this study is shown in Tables 2 and 3. These were se-
lected on the basis of previously published genome wide association data, indicating SNP 
association with RA13,14. Genotyping was undertaken in the laboratory of Dr Katherine Simi-
novitch at the University of Toronto, and the multiplexed SNP assays were performed on 
the Sequenom Mass Array iPLEX platform (Sequenom, Inc., San Diego, CA, USA). Allele-
specific extension products were plated onto a SpectroCHIP (Sequenom, Inc.) subjected 
to mass spectrometric analysis, and the genotypes were identified using SpectroCALLER 
software (Sequenom, Inc.).
Data analysis
The genotyping data for all individuals tested were subjected to quality control and indi-
viduals with genotype call rates less than 95% were removed. For each marker, genotype 
data quality was verified by testing the Hardy-Weinberg equilibrium in the control samples. 
The SNPs included in the study met the minimum quality control standards, with call rate 
greater than 95%, MAFs more than 1% and deviation from the Hardy-Weinberg equilibrium 
at P> 0.0001.
The SNP associations with RA were tested using the Plink software version 1.06 (http://
pngu.mgh.harvard. edu/~purcell/plink/summary.shtml) and SAS version 9.1.3 (SAS Insti-
tute Inc., Cary, NC, USA). As all the SNP associations with RA have been previously made 




Non-HLA genes modulate the risk of RA
In total, there were 854 NAN individuals (338 RA cases and 516 controls). In all, 31 individu-
als were removed for low genotyping, and after quality control, 333 cases and 490 controls 
were retained for analysis. The statistical power was evaluated by the software ‘The CaTS 
Power Calculator’ (Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, 
USA) for this study, with a total of 823 subjects consisting 333 cases and 490 controls. We 
assumed the estimated disease prevalence of 0.025, disease allele frequency 0.19, geno-
typic relative risk 1.5 and Type-1 error alpha 0.05.
Association analyses were performed using allelic, genotypic, minor allele dominant (ma-
jor allele recessive) and minor allele recessive models. In analyzing the SE positive sub-
jects 631 individuals (277 RA cases and 354 controls) were included. In all, 28 individuals 
were removed for low genotyping, and after quality control, 273 cases and 330 controls 
were retained. As with the entire population, association analyses were undertaken with 
all genetic models for this data set. Interaction between SE and MMEL1-TNFRSF14 was 
further tested using a multiplicative interaction model (risk factor 1 negative + risk factor 2 
negative versus risk factor 1 positive + risk factor 2 positive), as previously described34. A 
logistic regression model was also tested, in which an interaction term between SE and the 
AA genotype of MMEL1-TNFRSF14 was added.35 The power to detect the association is 
89% using an additive model and is 75% using a dominant model.
resulTs
The demographic and clinical features of the patient and control populations are shown in 
Table 1. As is typical of other RA populations, this was a predominantly female population. 
Although there was also a female predominance in the control population, the frequency 
was significantly lower than in the RA patients (82 versus 63%, P<0.01). As we have pre-
viously shown in this population, the available RA autoantibody data indicated that, ap-
proximately 90% of this cohort was rheumatoid factor (RF) and anti-citrullinated protein 
antibody (ACPA) positive22. The overall prevalence of one or two copies of SE (SE/x) was 82 
and 68% for RA patients and controls, respectively (P<0.01). The number of patients and 
controls with two copies of SE (SE/SE) was 32 and 23%, respectively. The two most com-
mon SE alleles were HLA-DRB1*0404 (43 and 32% in RA cases and controls, respectively) 
and *1402 (31 and 29% in RA cases and controls, respectively).
RA (n = 333) % Controls (n = 490) % P-value
Females 82 63 <0.01
RF positive 88 (223/255) - -
Anti-CCP positive 91 (74/81) - -
SE/x genotype 82 68 < 0.01
SE/SE genotype 32 23 < 0.01
Table 1. Clinical and immunogenetic characteristics of the study populations  
Abbreviations: Anti-CCP, anti-cyclical citrullinated protein; RA, rheumatoid arthritis; RF, rheumatoid 




We sought to determine non-HLA genes that may contribute to the development of RA 
in the NAN population. We tested SNPs that have been previously shown to be associ-
ated with RA; using candidate gene and GWAS approaches, these studies having been 
performed primarily in Caucasian populations. Table 2 compares the minor allele frequen-
cies (MAFs) detected in the NAN control population to that reported in the GWAS.23 The 
genotype distribution and MAF for the SNPs detected in the NAN RA cases and controls 
is shown in Table 3. The data in Table 3 indicate that genotypic distribution for MMEL1-
TNFRSF14, FCRL3 and CCL21 differed significantly between controls and RA patients. 
The MAF for MMEL1-TNFRSF14 tended to be lower in RA patients (odds ratio (OR) 0.82, 
95% confidence interval (CI) 0.7-1.0, P = 0.08) while being higher for TRAF1-C5 (OR 1.23, 
95% CI 1.0-1.5, P = 0.06).
Gene SNP Population Minor Major MAF OR P-value
MMEL1- 
TNFRSF14*
rs3890745 NAN G A 0.31 0.82 0.079
Caucasian C T 0.32 0.89 3.6E—6
REL rs13031237 NAN T G 0.23 0.91 0.393
Caucasianb T G 0.37 1.13 7.9E—7
STAT4 rs7574865 NAN T G 0.29 1.01 0.981
Caucasianb T G 0.22 1.16 2.9E—7
CTLA4 rs3087243 NAN A G 0.37 1.06 0.601
Caucasianb A G 0.44 0.87 1.2E—8
TNFAIP4 rs10499194 NAN T C 0.12 1.22 0.199
Caucasianb T C 0.27 1.91 7.4E—4
CCL21 rs2812378 NAN C T 0.38 0.92 0.994
Caucasianb G A 0.34 1.10 1.0E—4
TRAF1-C5 rs3761847 NAN G A 0.29 1.23 0.062
Caucasianb G A 0.43 1.13 2.1E—7
KIF5A-PIP4K2C rs1678542 NAN G C 0.30 0.94 0.547
Caucasianb G C 0.38 0.91 2.0E—4
Abbreviations: GWAS, genome wide association scans; MAF, minor allele frequencies; NAN, North 
American Natives; OR, odds ratio; SNP, single-nucleotide polymorphisms. aBases used for genotyp-
ing the minor allele of rs3890745 are the complementary bases to those reported in GWAS, but the 
data indicate a comparable MAF in both populations.bCaucasian MAF data based on data published 
in Stahl et al.23        
Table 2. Comparison of the MAF for SNPs detected with >5% frequency in the NAN control popula-





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We explored models other than the genotypic and allelic models that may potentially better 
explain the association between individual SNPs and RA, in particular minor allele domi-
nant and minor allele recessive models. These models examine associations on the basis 
of the homozygous and heterozygous states for each SNP, as gene dosage may impact 
on risk. Figure 1 compares the OR detected for each SNP using an allelic model (Figure 
1a) and a minor allele dominant model (Figure 1b). The latter model compares the het-
erozygous + minor allele homozygous states to the homozygous major allele state (Aa + 
aa versus AA). This analysis further demonstrates the significant protective effect of the 




Because of the high frequency of SE alleles in this population, we analyzed the panel of 
SNPs in the SE positive cases and controls. These data are shown in Table 4. On the basis 
of this analysis, we tested MMEL1-TNFRSF14 and TRAF1-C5 in minor allele dominant 
and recessive models. These data are shown in Table 5 and demonstrate the strength of 
the RA association in the minor allele dominant model, particularly when comparing only 
SE positive cases and controls. In the case of TRAF1-C5 minor allele, the association was 
positive, whereas the association with the MMEL1-TNFRSF14 minor allele was in the op-
posite direction.
Figure 1. Log odds ratio for association between a panel of non-HLA SNPs and RA in a NAN popu-
lation. (a) Represents an allelic model; (b) represents a minor allele dominant model (AA versus Aa + 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Finally, we determined whether there was evidence of multiplicative interaction between 
SE and MMEL1-TNFRSF14. These data are shown in Table 6. As the minor allele is pro-
tective in a dominant manner, we tested the interaction between SE and the homozygous 
major allele state of the MMEL1-TNFRSF14 SNP (AA) as risk factors. The data indicate 
that, compared with the absence of both risk factors (OR = 1), having both SE and AA is 
associated with a substantial increase in risk, compared with having only one of these risk 
factors (OR 2.6, 95% CI 1.7-4.1, P< 0.0001). This interaction was further confirmed using 
a logistic regression model, where an interaction term SE*AA was added to a model that 
included both risk factors and gender. In this model, the interaction term was significantly 
associated with RA (OR 2.2, 95% CI 1.1-4.6, P = 0.03). An analysis of TRAF1-C5 as a risk 
factor showed a similar interaction with SE (OR 2.3, 95% CI 1.2-2.3, P<0.001). 
All controls and cases SE positive controls and cases
OR 95% CI P-value OR 95% CI P-value
Minor allele dominant model 
(Aa+aa vs AA)
MMEL1-TNFRSF14  0.69 0.5-0.9 0.009 0.61 0.4-0.8 0.002
TRAF1-C5    1.27 1.0-1.7 0.096 1.56 1.1-2.2 0.007
Minor allele recessive model  
(aa vs Aa+AA)
MMEL1-TNFRSF14  1.14 0.7-1.8 0.620 1.45 0.8-2.5 0.200
TRAF1-C5    1.36 0.9-2.2 0.220 1.89 1.1-3.3 0.040
Table 5. OR for RA association with MMEL1-TNFRSF14 and TRAF-C5, using a minor allele dominant 
(top panel) and minor allele recessive model (bottom panel), in the entire population of cases and 
controls (left panels) and SE-positive cases and controls (right panels)
Abbreviations: CI, confidence interval; OR, odds ratio; RA, rheumatoid arthritis; SE, shared epitope.
MMEL1-TNFRSF14  
AA genotype
SE allele Cases/ controls OR (95% CI) P-value
0 0 35/87 1.0
0 1 123/203 1.5 (1.0-2.4) 0.06
1 0 26/73 0.9 (0.5-1.6) 0.60
1 1 154/151 2.6 (1.7-4.1) <0.0001
Table 6. Evidence for interaction between the homozygous major allele (AA) genotype of MMEL1-
TNFRSF14 and SE    
Abbreviations: CI, confidence interval; OR, odds ratio; SE, shared epitope. The reference genotype 
with both risk factors absent is shown in the first row. The presence of the individual risk factors 




Non-HLA genes modulate the risk of RA
dIscussIon
NAN populations have been shown to have a high prevalence of RA, compared with most 
other populations worldwide4. Moreover, as is the case with a number of the NAN popula-
tions that have been studied, we have shown that the Cree/Ojibway population in Central 
Canada has a high prevalence of SE alleles, specifically *0404 and *1402.8 Because of 
the high prevalence of SE in the population, we looked for SNP associations in non-HLA 
regions that may further predispose NAN individuals to RA, or alternatively, protect them 
from the risk associated with SE. In the current study, we show that several non-HLA 
SNP were marginally associated with RA risk in the NAN population, but that SNPs in the 
TRAF1-C5 and MMEL1-TNFRSF14 regions interacted significantly with SE, albeit in oppo-
site directions with the former increasing risk and the latter being protective in the presence 
of the HLA-DRB1 risk.
In comparing the SNP allele frequencies in the NAN population with those reported in pre-
vious GWAS and candidate gene studies, some differences in SNP MAFs were apparent 
(Table 2). One potential confounder in such a comparison is that of ethnic admixture in the 
NAN population. However, to minimize admixture effects, inclusion in this study required 
each individual to have at least three of four grandparents of NAN background. Although 
this strategy does not eliminate the possibility of Caucasian (or other ethnic) admixture, our 
previously reported HLA data suggest that the frequency of the Caucasian HLA-A1 allele 
in this NAN population is <5%.7
The association with MMEL1-TNFRSF14 was initially demonstrated in a meta-analysis 
of three GWAS of approximately 4000 European patients and 12 000 European controls, 
whereas it had not been detected in any of the smaller individual GWAS14. In that study, 
the minor allele was also shown to have a protective effect on disease development (OR = 
0.86), which is similar to what we detect in the current study. The modeling we performed 
suggested that the homozygous state for the major allele conferred the highest risk, and 
that the presence of the minor allele was indeed protective in a dominant manner. This 
finding is particularly relevant to a population, where most individuals carry one or more 
SE alleles, the primary risk factor for RA susceptibility. In such a population, it is likely that 
other genes have an important modulating effect on the HLA-DRB1 associated risk.
Recently, a study of Spanish RA patients and controls demonstrated an epistatic interac-
tion between MMEL1-TNFRSF14 (as identified by rs6684865) and another TNFR super-
family member, TNFRSF6B (as identified by rs4809330), which increased the risk of RA24. 
TNFRSF6B alone did not affect RA risk. Moreover, although the genotypic distribution of 
MMEL1-TNFRSF14 was similar to that of NAN controls in our study, the association with 
MMEL1-TNFRSF14 alone was marginally demonstrable only in the replication study and 
not in the primary study, even after stratification for SE. The reasons for these differences 
remain unclear, but may relate to the distribution of the SE alleles in the Spanish popula-
tion. The causal gene in the MMEL1-TNFRSF14 association has not been identified, as 




on gene function. It is appealing to speculate that TNFRSF14 is indeed the RA associated 
gene as it is a key homeostatic molecule involved in T-cell activation25. Also known as her-
pes virus entry mediator for its role as a herpes virus receptor, TNFRSF14 is expressed on 
the surface of T cells and synovial fibroblasts and activates the canonical nuclear factor-kB 
(NF-KB) pathway upon ligation of LIGHT, a TNF super family member26-28.
TRAF1-C5 was previously reported to be associated with RA in primarily Caucasian popu-
lations29. The OR for association with the minor allele of the rs3761847 SNP was reported 
at 1.32, which is comparable to an OR of 1.23 we report in the NAN population, using the 
same SNP. We further demonstrate that the OR is increased to 1.48 when analyzing SE 
positive cases and controls, and as with MMEL1-TNFRSF14, there is an indication of a 
significant interaction with SE. In both cases, the minor allele appeared to act in a domi-
nant manner, albeit in opposite directions. This conclusion has to be interpreted cautiously 
however, in view of the challenges inherent to analysis of epistasis between gene loci in 
complex disorders such as RA30.
TRAF1 and TNFRSF14 are both involved in the activation of NF-KB, a central pathway in 
the pathogenesis of RA. Indeed, many of the non-HLA SNPs that have been associated 
with RA are centered around the NF-KB pathway, and include TNFAIP3, CD40 and REL in 
addition to TRAF1 and TNFRSF14. The NF-KB pathway is activated by TNFa and IL-1P, 
two key cytokines in RA pathogenesis, and in turn, regulates the transcription of a gene 
signature that promotes both the chronic inflammatory response and the matrix degrad-
ing mechanisms that are a characteristic feature of the disease. SE encoding HLA-DRB1 
alleles have been hypothesized to predispose to RA by efficiently presenting citrullinated 
antigens to T cells31, and in turn, generating immune responses that target endogenous 
citrullinated antigens such as cit-vimentin, cit-fibrinogen and cit-enolase32. It is thus pos-
sible that in the context of such facilitated antigen presentation by SE encoding alleles, the 
subsequent downstream activation of immune effector cells such as T cells and macro-
phages is modulated by polymorphic variants of molecules in the NF-KB pathway, such 
as TRAF1 and TNFRSF14. To date, the functional consequences of these polymorphisms 
have not been demonstrated, nor is it clear that they are indeed the disease causal genes.
In addition to MMEL1-TNFRSF14 and TRAF1-C5, a number of other marginal associa-
tions were detected that perhaps would be more significant if the study had greater power. 
Perhaps, most surprising was the absence of a clear association with the R620W allele of 
PTPN22, this having been shown to predispose to RA in multiple populations. We found a 
frequency of 3% in controls for the R620W genotypes in the NAN population, as identified 
by rs2476601, and an almost identical genotypic distribution for a second SNP found in the 
PTPN22 gene, rs6679677. Although this frequency is somewhat lower than the 12-15% 
reported in Caucasian populations, it contrasts with that in several present-day East Asian 
populations in which this polymorphism is absent15-17. We were also unable to confirm a 




Non-HLA genes modulate the risk of RA
conclusIon
In summary, we have evaluated genomic RA risk in a NAN population with a high preva-
lence of RA. A spectrum of SNPs previously identified using GWAS and candidate gene 
approaches were tested. The data indicate that, in this population where RA-associated 
SE alleles are prevalent, there is a modulatory effect on disease risk from non-HLA genes, 
particularly MMEL1-TNFRSF14 and TRAF1-C5.
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Based upon findings in juvenile idiopathic arthritis, the genetic contribution of the VTCN1 
region to rheumatoid arthritis (RA) susceptibility and anticitrullinated protein antibody 
(ACPA) status was investigated. VTCN1 is known to play a pivotal role in regulation of the 
immune system and, in soluble form, has previously been associated with higher disease 
activity. 
Methods 
Ten VTCN1 polymorphisms were genotyped in 1237 Dutch patients with RA and 1055 
healthy controls. Significant findings were replicated in two independent RA populations of 
northern European descent consisting of 2826 patients and 2122 healthy controls. Allele 
distribution was analysed using a χ2 test and combined analysis of all studies was per-
formed using the Mantel-Haenszel fixed effects method.
Results
A significant association with two polymorphisms was observed in the Dutch RA popula-
tion. Replication of these findings showed an overall significant association with rs4376721 
and rs10923217 (OR 1.13, 95% CI 1.03 to 1.24, p = 0.013 and OR 0.78, 95% CI 0.67 to 
0.91, p = 0.0011, respectively). Stratification for ACPA status revealed an association in the 
ACPA-negative subset for rs4376721 (OR 1.19, 95% CI 1.05 to 1.35, p = 0.0071), while no 
overall significance could be observed in the ACPA-positive population. rs10923217 was 
associated with both subsets of the disease. 
Conclusion




Novel genetic association of VTCN1 with RA
InTroducTIon
Although the aetiology of rheumatoid arthritis (RA) is largely unknown, it is thought that 
both environmental and genetic factors have a role in the development of the disease1. To 
date, over 30 genetic regions have been identified to associate with RA susceptibility. Most 
of these loci have been identified by genome-wide association studies (GWAS) performed 
in autoantibody-positive patient populations2. It is known, however, that RA is a heteroge-
neous disease and data indicate that distinct risk factors play a role in the anticitrullinated 
protein antibody (ACPA) subsets3. Further investigation in these subsets is needed to elu-
cidate the genetic backgrounds.
Although many genes for complex diseases such as RA have been identified, it is thought 
that only part of the genetic susceptibility to these diseases can be explained by these loci. 
Part of this ‘missing heritability’ is speculated to be due to rare genetic variations which 
can be identified by resequencing genomes of patients4. Additionally, it is well recognised 
that GWAS are probably underpowered to detect all common disease variants and further 
investigation of these variants might lead to novel genetic associations5.
As more autoimmune susceptibility loci are being identified, it has become clear that part 
of these genes overlap between autoimmune diseases. Recently, a GWAS in juvenile id-
iopathic arthritis (JIA) identified the VTCN1 region to be associated with JIA and observed 
this region as the strongest signal next to human leucocyte antigen6.
VTCN1 encodes B7-H4 which has been reported as a negative regulator of T cell respons-
es in vitro by inhibiting proliferation and cytokine production7,8. However, in B7-H4 deficient 
mice, no strong phenotype of hyperactivation of T and B cells was observed9. It has been 
shown that the protein is expressed in tumour-associated suppressive macrophages8. Re-
cently, it was found that high levels of the soluble form of B7-H4 are seen more frequently 
in patients with RA than in healthy controls and are associated with higher disease activity 
as measured by the 28-joint disease activity score10. Likewise, in B7-H4 knockout mice the 
progression of inflammation in a collagen-induced arthritis model was accelerated com-
pared with wild-type mice, which suggests a relevant role for B7-H4 in arthritis10.
The aim of the present study was to identify the genetic contribution of the VTCN1 region 
to RA susceptibility and the clinically well-defined subsets, characterised by ACPA status.
MeTHods
Patients
A total of 1257 patients with RA, all of whom met the American College of Rheumatology 
(ACR) 1987 criteria, were recruited from hospitals in the western part of The Netherlands. 
ACPA status was obtained for 940 patients. The characteristics of the patients have been 
described previously11. The control group consisted of 1060 healthy subjects randomly 





For validation purposes, two independent western European cohorts were included. The 
first cohort consisted of 953 Norwegian patients with RA and 1121 healthy Norwegian 
controls. All patients fulfilled the ACR criteria and originated from two cohorts: the Oslo RA 
register (ORAR) and the Norwegian arm of the European Research on Incapacitating Dis-
ease and Social support. Follow-up has been described previously12,13. ACPA status was 
available for 893 patients. The second cohort consisted of 1908 Swedish patients with RA 
and 1061 healthy Swedish controls recruited from different parts of Sweden between May 
1996 and December 2005. All patients originated from the Epidemiological Investigation 
of Rheumatoid Arthritis (EIRA) study and met the ACR criteria for RA. ACPA status was 
obtained for all patients. A more detailed description of the EIRA study has been presented 
previously14. The study was approved by the ethics committee at the Karolinska Institutet 
and by the Regional Stockholm ethics committee.
The power to detect an association within the combined population was >80%, calculated 
by Quanto, assuming an OR of 1.20.
Genotyping methods
Ten single nucleotide polymorphisms (SNPs) were selected on the basis of their previ-
ous significant association with JIA.6 rs6673837, rs2358817, rs10923217, rs6669320, 
rs10923223 and rs12046117 were genotyped in 985 patients and 865 controls using Mas-
sArray matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (Se-
quenom, San Diego, California, USA) with a success rate of >97%. rs2051047, rs4376721, 
rs12038533 and rs7415876 were genotyped in 1257 patients and 1060 controls using Taq-
man allelic discrimination assays (AppliedBiosystems, Bleiswijk, The Netherlands) with a 
success rate of >95%.
In the Norwegian dataset, rs4376721 and rs10923217 were genotyped using MassArray 
matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (Sequenom). 
The genotyping success rate was >95%.
Data from the Swedish EIRA study were retrieved from GWAS published previously15. After 
removing outliers, a total of 1147 ACPA-positive patients and 1079 controls were used for 
analysis. 
Statistical analysis
Analysis of allele distribution for association in the Dutch population and carriage of the mi-
nor allele in the replication study was performed using a χ2 test with one degree of freedom. 
ORs and 95% CI were calculated using the Statcalc module of EpiInfo Software (Centers 
for Disease Control and Prevention, Atlanta, Georgia, USA). P values <0.05 were consid-
ered significant and genotype frequencies in controls did not deviate from Hardy-Weinberg 
equilibrium (p<0.05). Combined analysis of the genotypes of all studies was performed us-
ing the Mantel-Haenszel fixed effects method. Heterogeneity across studies was analysed 




Novel genetic association of VTCN1 with RA
resulTs
Ten polymorphisms which have previously been shown to be associated with JIA were 
genotyped in a Dutch RA population. Both rs4376721 and rs10923217 showed significant 
associations with RA (OR 1.21, 95% CI 1.07 to 1.38, p = 0.003 and OR 0.87, 95% CI 0.76 
to 0.99, p = 0.031, respectively; table 1).
In this analysis we did not correct for multiple testing as we wished to replicate all the 
associations observed in a second stage. To validate the observed associations, the two 
significant polymorphisms rs4376721 and rs10923217 were replicated in two independent 
RA populations of western European descent. Since the genotype frequencies indicated a 
dominant inheritance, carriage of the minor allele was also analysed. A p value <0.025 was 
considered significant.
Allele Cases Controls 1 vs 2







rs6673837 G A 980 619 317 44 0.21 853 542 265 46 0.21 1.02 (0.86 
to 1.20)
0.845 0.080
63.1 32.35 4.5 63.54 31.07 5.4
rs2358817 C T 978 831 1 41 6 0.08 835 699 1 30 6 0.09 1.10 (0.86 
to 1.40)
0.455 1.000
85.0 14.42 0.6 83.71 15.57 0.7
rs2051047 G A 1 239 1 040 1 87 12 0.09 1057 885 164 8 0.09 1 .00 (0.81 
to 1.24)
0.999 0.843
83.94 1 5.09 1.0 83.73 15.52 0.8
rs4376721 T G 1 237 621 521 95 0.29 1055 481 455 119 0.33 1.21 (1.07 
to 1.38)
0.003 0.490
50.2 42.12 7.7 45.59 43.13 11.28
rs10923217 G C 968 230 495 243 0.51 836 245 395 196 0.47 0.87 (0.76 
to 0.99)
0.031 0.145
23.76 51.14 25.1 29.31 47.25 23.44
rs6669320 G A 976 706 250 20 0.15 845 615 203 27 0.15 1 .03 (0.85 
to 1.24)
0.768 0.060
72.34 25.6 2.0 72.7 24.0 3.195
rs12038533 C A 1 237 984 246 7 0.11 1057 839 203 15 0.11 1 .05 (0.87 
to 1.28)
0.576 0.529
79.55 1 9.89 0.6 79.3 19.2 1.4
rs7415876 G C 1 241 871 335 35 0.16 1057 742 279 36 0.17 1 .02 (0.87 
to 1.20)
0.794 0.148
70.19 26.99 2.8 70.2 26.4 3.4
rs10923223 T C 981 682 273 26 0.17 852 612 226 14 0.15 0.88 (0.73 
to 1.06)
0.170 0.224
69.52 27.83 2.7 71.83 26.53 1.6
rs12046117 C T 958 71 5 227 16 0.14 844 631 200 13 0.13 0.99 (0.81 
to 1.20)
0.910 0.656
74.63 23.7 1.7 74.76 23.7 1.5
Table 1. Analysis of 10 SNPs in the VTCN1 region in a Dutch rheumatoid arthritis population
1, major (common) allele; 2, minor (rare) allele. MAF, minor allele frequency; SNP, single nucleotide 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A trend towards association was observed in the Norwegian cohort for both polymor-
phisms (rs4376721: p = 0.0456; rs10923217: p = 0.0497). This effect was in the same 
direction as that seen in the Dutch discovery cohort (table 2).
In the Swedish population only data on rs4376721 were available for analysis. Neither 
rs10923217 nor a proxy of any kind was included in the Swedish GWAS. In this study, 
rs4376721 did not indicate significance. Nonetheless, a combined analysis of all three inde-
pendent populations did show a significant association (p=0.01). Likewise, for rs10923217, 
an overall significant association could be established in the combined Dutch and Norwe-
gian cohort (p=0.001). Notably, no heterogeneity was observed between the different study 
populations (p>0.05) and in all studies the same allele contributed to disease (table 2). The 
linkage disequilibrium between the two polymorphisms was limited with a r2 of 0.30 and 
a D’ of 0.85.
The contribution of the VTCN1 region to the ACPA subsets was also analysed. Stratifica-
tion for ACPA status showed rs4376721 to be significantly associated in the ACPA-nega-
tive subset compared with healthy controls, but not in the ACPA- positive subset. The OR 
of the ACPA-negative subgroup was slightly higher than in the ACPA-positive subgroup, 
although no statistical difference was observed in the ACPA-negative subset compared 
with the ACPA-positive subset (OR 1.10, 95% CI 0.96 to 1.26, p=0.145). In ACPA-negative 
disease, all minor allele frequencies were biased in the same direction while, in ACPA-
positive disease, more heterogeneity was observed (figure 1).
Stratifying for ACPA reactivity for rs10923217 demonstrated an overall association of this 
polymorphism for both subsets of the disease (table 2).
Expression data from the GenCord database16 showed a significant correlation between 
rs6428686 (a perfect proxy for rs4376721) and VTCN1 transcript levels, with the risk allele 
G being associated with lower expression in primary T cells (p = 0.0069). A similar pattern 
was observed in lymphoblastoid cell lines (p = 0.067; see figure S1 in online supplement). 
These data indicate that the identified genetic variant has an impact on basal VTCN1 ex-
pression in non-progenitor immune cells.
dIscussIon
In the present study a novel genetic risk factor for RA susceptibility was identified in a 
Dutch RA population and replicated in independent populations of northern European de-
scent.
Previous studies in RA have suggested that associated loci predispose to specific subsets 
of the disease, characterised by ACPA status3,17. Also, non-genetic data indicate that AC-
PA-positive disease behaves differently from ACPA-negative disease13,18. It is therefore of 
relevance to analyse these potentially different forms of arthritis in a separate manner. Our 
results indicate that the VTCN1 region seems to associate mainly with an ACPA-negative 




Novel genetic association of VTCN1 with RA
Figure 1. Meta-analysis of association of rs4376721 for rheumatoid arthritis susceptibility and antic-
itrullinated protein antibody status compared with healthy controls in three northern European rheu-




Nonetheless, no significant difference was observed when the ACPA-negative subset was 
directly compared with the ACPA-positive subset. Although this lack of significance is pos-
sibly due to insufficient power (for the present sample numbers the power is ~72%), no 
final conclusion on this aspect can be drawn. Additional replication in independent cohorts 
is therefore necessary to identify a differential effect of the VTCN1 locus in the two subsets 
of RA.
The polymorphisms typed within this study were selected on the basis of their previous 
significant association with JIA6. It is notable that the association pattern of the variants 
seems to be different between the two diseases. First, the most significant SNP in JIA was 
not significantly associated within the Dutch cohort. Also, the distribution of the genotype 
frequencies is different between RA and JIA, which is mainly visible for rs4376721. There-
fore, very subtle differences in minor allele frequency in the control or patient groups are 
prone to affect data and lead to different results, indicating the need for replication. One 
could also speculate that protein function or expression is affected differently by differ-
ent genetic variants, which could explain the difference in disease outcome and disease 
course. Although indirect, and although it is not known whether VTCN1 is constitutively ex-
pressed, analysis of expression data from the GenCord database indeed shows differential 
expression for the different genotypes in lymphoid cells.
conclusIon
In conclusion, this study has identified the VTCN1 region as a new genetic region associ-
ated with susceptibility to RA.
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Variants of gene for microsomal 
prostaglandin E2 synthase show 
association with disease and severe 






Microsomal PGE synthase 1 (mPGES-1) is the terminal enzyme in the induced state of 
prostaglandin E2 (PGE2) synthesis and constitutes a therapeutic target for rheumatoid ar-
thritis (RA) treatment. We examined the role of the prostaglandin E synthase (PTGES) gene 
polymorphism in susceptibility to and severity of RA and related variations in the gene to 
its function.
Methods 
The PTGES gene polymorphism was analyzed in 3081 RA patients and 1900 controls from 
two study populations: Swedish Epidemiological Investigation of Rheumatoid Arthritis 
(EIRA) and the Leiden Early Arthritis Clinic (Leiden EAC). Baseline disease activity score 
(DAS28) was employed as a disease severity measure. mPGES-1 expression was analyzed 
in synovial tissue from RA patients with known genotypes using immunohistochemistry.
Results 
In the Swedish study population, among women a significant association with risk for RA 
was observed for PTGES single-nucleotide polymorphisms (SNPs) in univariate analysis 
and for the distinct haplotype. These results were substantiated by meta-analysis of data 
from EIRA and Leiden EAC studies with overall OR 1.31 (95% confidence interval 1.11-
1.56). Several PTGES SNPs were associated with earlier onset of disease or with higher 
DAS28 in women with RA. Patients with the genotype associated with higher DAS28 ex-
hibited significantly higher mPGES-1 expression in synovial tissue.
Conclusion 
Our data reveal a possible influence of PTGES polymorphism on the pathogenesis of RA 
and on disease severity through upregulation of mPGES-1 at the sites of inflammation. 





Association of PTGES with inflammation in RA
InTroducTIon
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent sy-
novial inflammation resulting in joint destruction and severe disability. It is one of the most 
common complex autoimmune diseases, with up to 1% prevalence, and a higher preva-
lence, activity and earlier disease onset in women. Genetic factors significantly contribute 
to the development of RA and its severity1. The major genetic risk factor for RA is the 
shared epitope alleles of the HLA-DRB1 gene locus2,3. Recently several common genetic 
variants have been discovered outside HLA-DRB1 locus, identifying important biological 
pathways predisposing to RA (for a review, see Raychaudhuri4).
Prostaglandin E2 (PGE2) is one of the key mediators of inflammation, pain and joint de-
struction in RA, and its production is an important target of anti-inflammatory drugs. Hence 
PGE2 biosynthetic pathway is of considerable interest to gene association and pharma-
cogenetic studies5,6. PGE2 is produced by conversion of arachidonic acid to PGH2 by 
cyclooxygenases (COX-1/COX-2) and subsequent conversion of PGH2 to PGE2 by ter-
minal PGE synthases. Microsomal PGE synthase 1 (mPGES-1) is the terminal enzyme in 
the induced PGE2 production at the sites of inflammation7,8 and has an important role in 
the pathogenesis of inflammatory arthritis9,10. In humans, mPGES-1 expression is induced 
by proinflammatory cytokines in RA synovial fibroblasts and synovial fluid monocytes11,12 
and markedly up-regulated in RA synovial tissue13. In mice with experimental arthritis, ge-
netic deletion of mPGES-1 results in significantly reduced disease incidence, severity and 
pain9,10. mPGES-1 is recognized as an alternative target for anti-inflammatory treatment 
with improved selectivity and safety compared with COX-1/COX-2.8
The human mPGES-1 is encoded by prostaglandin E synthase (PTGES) gene, which is 
localized at chromosome 9q34.3, spans 14.8 kb and contains three exons. According to 
NCBI single-nucleotide polymorphisms (SNPs) database, there are 249 SNPs in the PT-
GES gene region, including four coding SNPs (two synonymous and two non-synonymous 
SNPs). Whereas none of the studied variants in PTGES gene had a significant effect on the 
risk of lymphoma,14 non-fatal myocardian infarction or ischemic stroke,15 and breast cancer 
susceptibility,16 in a large-scale association study one SNP in the 5’ region of the PTGES 
gene was associated with hypertension in women in the Japanese population17. SNPs in 
the PTGES gene could modify enzyme expression levels or activity and alter inducible 
PGE2 biosynthesis. Consequently, PTGES gene polymorphisms might contribute to inter-
individual differences in susceptibility to or severity of RA, as well as clinical response to 
future mPGES-1 inhibitors. Hence, PTGES genetics may have clinical importance from 
disease risk assessment to choice of personalized treatment in RA.
Here, we studied the association between PTGES gene polymorphisms and risk and se-
verity of RA. In addition, we examined whether PTGES gene polymorphism could contrib-




PaTIenTs and MeTHods 
Patients
In this study, two independent cohorts have been included: Swedish Epidemiological In-
vestigation of Rheumatoid Arthritis (EIRA) and Leiden Early Arthritis Clinic (Leiden EAC). 
The first cohort consisted of 2012 RA patients and 1033 controls matched by age, sex and 
residential area from the EIRA, a population-based case-control study in Sweden (Table 
1).A case was defined as a person who was diagnosed for the first time with RA based on 
the diagnostic criteria of the American College of Rheumatology18. Data regarding age of 
disease onset were available for all patients, and data regarding baseline disease activity 
score (DAS28) for 887 (44%) RA patients. Further characteristics of the EIRA study are 
described elsewhere19.
At the replication stage, the second cohort consisted of 1069 Dutch Caucasian individu-
als with RA who fulfilled the ACR classification criteria for RA and 867 controls, who were 
unrelated Dutch Caucasians with no history of RA from EAC (Table 1). More details about 
the EAC study population have been described elsewhere20. Approval was granted by the 
regional ethics committees and all participants gave their informed consent to participate 
in the study.
SNP genotyping
In all, 11 SNPs were selected across the PTGES gene locus and flanking regions (Figure 1). 
The selection was based on the minor allele frequency being higher than 10% according to 
NCBI for all SNPs except for rs11792431 (minor allele frequency 2.5%). In the replication 
phase, we genotyped three SNPs in PTGES locus, which showed significant association 
with RA risk. Genotyping was performed using TaqMan SNP genotyping assays (Applied 
Biosystems, Europe BV, The Netherlands). The average genotyping call rate was 96.6%, 
varying from 95 to 98% for different SNPs.
In addition, we included in the analysis data from our previous genome-wide association 
scan21 for 14 SNPs in the PTGES locus and inter-gene regions with neighboring PRRX2 
and TOR1B genes (Figure 1). Genotyping was performed on the Illumina HumanHap300 
(version 1.0) array (Illumina, San Diego, CA, USA)21.
Immunohistochemical analysis
Synovial tissue biopsy specimens from 24 RA patients from EIRA carrying different PTGES 
genotypes were obtained during arthroscopy. Synovial tissue samples were snap frozen 
and kept at -70°C until sectioned. Staining of cryostat sections with rabbit polyclonal anti-
human mPGES-1 antiserum was performed as previously described13. Irrelevant rabbit IgG 
was used as a negative control. Stained tissue sections were examined using a Polyvar II 
microscope (Reichert-Jung, Vienna, Austria) and photographed with a digital Leica cam-
era 300F (Leica, Cambridge, UK). The positive staining was assessed quantitatively using 
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Statistical analysis
Genotype and allele frequencies in the patient and the control groups were compared us-
ing the χ2-test and/or Fisher’s exact test when appropriate. Haplotype frequencies were es-
timated using HaploView 4.0 (http:// www.broad.mit.edu/mpg/haploview/index.php), and 
the permutation test was set to 1,000,000 permutations for the single markers and for the 
haplotypes, with P<0.05 for significance of empirical P-value. An odds ratio (OR) with 95% 
confidence interval (CI) was calculated for the association between different genetic factors 
and risk of RA. Evaluation of linkage disequilibrium and deviations from Hardy-Weinberg 
equilibrium were performed using HaploView. The distribution of genotypes for all studied 
SNPs within the RA group and within the control group was in agreement with Hardy-Wein-
berg equilibrium (P>0.05). Before combining for meta-analysis, the EIRA and Leiden EAC 
data were tested for the homogeneity in the ORs, using a Pearson χ2 goodness-of-fit test 
as described elsewhere22. In the meta-analysis of haplotype-frequency data, the RA cases 
versus controls were compared in EIRA and Leiden EAC studies using Mantel-Haenszel 
analysis assuming random effects for the ORs22.
In RA patients stratified by sex, the associations between PTGES polymorphisms and 
DAS28 and age at the first diagnosis of RA, as well as the results of functional study, were 
analyzed using Mann-Whitney’s U-test with Bonferroni corrections for multiple compari-
sons. P-values <0.05 were considered statistically significant.
Table 1 Clinical characteristics of EIRA and Leiden EAC studies
Characteristics EIRA Leiden EAC
No. of patients 2012 1069
No. of controls 1033 867
Country of origin Sweden The Netherlands
Female sex, patients (%) 70.4 64
Female sex, controls (%) 74.6 21.9
Age of onset, years (mean ±SD) 51.7 ± 12.7 56.4±15.4
Disease duration, years <1 <2
ACPA positive (%) (1265/2012) 62.8 (375/625a) 60
HLA-DRB1 SE (patients) (%) (1486/2012) 73.8 (590/842b) 70.1
Abbreviations: ACPA, anti-citrullinated peptide antibody; SE, shared epitope. Details on the EIRA 
study19 and the Leiden EAC study20 have been reported elsewhere. aThe number of patients with 





PTGES polymorphisms and risk of developing RA
In the discovery phase, we analyzed allelic and haplotype frequencies of 11 SNPs in the 
PTGES gene in the entire Swedish cohort, as well as in men and women separately. An 
association between the SNP rs16931419 and risk of RA was observed in the allelic model 
(women and men combined), but the difference was not significant after permutation test 
(Table 2). Among women three SNPs, rs10988484, rs11999368 and rs16931419, from a 
single linkage disequilibrium block in the gene locus downstream the PTGES gene showed 
higher minor allele frequencies in female RA patients compared with those in female con-
trols (Table 2). The association of the SNP rs16931419 with the risk of RA was still apparent 
after permutation test (OR 1.38; 95% CI 1.14-1.67, empirical P-value = 0.0082). Among 
men, a trend toward an association between the SNP rs3844048 and risk of RA was ob-
served, but this association was not statistically significant after permutation test (Table 2).
To exclude possible correlation with neighboring genes owing to extended linkage disequi-
librium, we expanded the analysis by including 14 SNPs in the PTGES locus and intergenic 
areas with the PRPX2 or the TOR1B genes using data from our previous genome-wide as-
sociation scan21 (Figure 1). There was no evidence for an association between SNPs in prox-
imity to the PRPX2 gene or the TOR1B gene and susceptibility to RA (data are not shown).
Figure 1 Linkage disequilibrium map for the PTGES locus (r2). The SNPs marked with numbers were 
analyzed in the EIRA case-control study. The SNPs marked with * were analyzed using data from our 
previous genome-wide association scan.
Fig.1
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OR (95% CI) P P*
The Swedish population
1 rs10988484 3' near gene T All 0.154 0.138 1.14 (0.98-1.33) 0.0966 NS
F 0.160 0.129 1.28 (1.07-1.54) 0.0076 0.0591
M 0.141 0.163 0.84 (0.63-1.12) 0.23 NS
2 rs11999368 3' near gene T All 0.148 0.134 1.12 (0.96-1.31) 0.15 NS
F 0.152 0.124 1.26 (1.05-1.52) 0.0138 0.1035
M 0.138 0.162 0.83 (0.62-1.10) 0.19 NS
3 rs16931419 3' near gene C All 0.149 0.127 1.2 (1.02-1.41) 0.02 NS
F 0.153 0.116 1.38 (1.14-1.67) 0.0010 0.0082
M 0.139 0.160 0.84 (0.63-1.14) 0.26 NS
4 rs2302821 3'-UNR C All 0.091 0.091 1.0 (0.83-1.21) 0.95 NS
F 0.093 1.0 0.93 (0.75-1.15) 0.49 NS
M 0.087 0.065 1.36 (0.91-2.04) 0.13 NS
5 rs4837404 Intron 2 G All 0.333 0.325 1.04 (0.92-1.16) 0.54 NS
F 0.334 0.323 1.05 (0.92-1.20) 0.44 NS
M 0.330 0.331 0.99 (0.80-1.24) 0.93 NS
6 rs10739757 Intron 2 C All 0.095 0.101 0.93 (0.78-1.12) 0.44 NS
F 0.092 0.102 0.89 (0.72-1.1) 0.27 NS
M 0.103 0.099 1.01 (0.91-1.12) 0.82 NS
7 rs2241270 Intron 1 T All 0.096 0.097 1.00 (0.94-1.06) 0.93 NS
F 0.096 0.096 1.00 (0.83-1.23) 0.95 NS
M 0.098 0.100 0.99 (0.70-1.39) 0.93 NS
8 rs11792431 Exon 1 A All 0.056 0.054 1.04 (0.82-1.32) 0.74 NS
F 0.053 0.052 1.00 (0.76-1.33) 0.94 NS
M 0.063 0.058 1.09 (0.71-1.69) 0.69 NS
9 rs10988496 5' near gene G All 0.104 0.104 1.00 (0.84-1.20) 0.96 NS
F 0.101 0.103 0.97 (0.79-1.20) 0.80 NS
M 0.101 0.107 1.00 (0.75-1.45) 0.81 NS
10 rs3844048 5' near gene G All 0.301 0.308 0.97 (0.86-1.09) 0.58 NS
F 0.303 0.291 1.05 (0.92-1.22) 0.40 NS
M 0.295 0.358 0.75 (0.60-0.93) 0.0114 NS
11 rs6478915 5' near gene G All 0.250 0.247 1.01 (0.89-1.15) 0.82 NS
F 0.252 0.232 1.11 (0.96-1.29) 0.16 NS
M 0.244 0.289 0.79 (0.63-1.01) 0.05 NS
The Dutch population
1 rs10988484 3' near gene T All 0.152 0.152 1.00 (0.83-1.19) 0.95 NS
F 0.151 0.129 1.20 (0.85-1.70) 0.28 NS
M 0.152 0.159 0.95 (0.74-1.22) 0.72 NS
2 rs11999368 3' near gene T All 0.145 0.141 1.03 (0.86-1.24) 0.74 NS
F 0.138 0.124 1.14 (0.82-1.62) 0.46 NS
M 0.157 0.146 1.08 (0.85-1.39) 0.49 NS
3 rs16931419 3' near gene C All 0.139 0.138 1.01 (0.84-1.22) 0.93 NS
F 0.131 0.116 1.16 (0.80-1.67) 0.42 NS
M 0.153 0.145 1.06 (0.83-1.36) 0.59 NS
Table 2 Minor allele frequencies of SNPs at PTGES locus in the Swedish and the Dutch populations





Further, we examined the frequency of haplotypes (only with the frequency above 0.01) 
based on the three SNPs significantly associated with the risk of RA. The frequency of the 
haplotype TTC (susceptible haplotype) was significantly higher in women with RA than in 
women without RA (OR 1.34; 95% CI 1.11-1.63, empirical P-value = 0.0077) (Table 3). The 
frequency of the opposite haplotype CCT (protective haplotype) was significantly lower in 
women with RA compared with controls (OR 0.78; 95% CI 0.66-0.93, empirical P-value = 
0.0172). We did not find significant associations between these haplotypes and RA risk 
among men (Table 3).
In the replication phase, we analyzed the association of the three SNPs, rs10988484, 
rs11999368 and rs16931419, with RA susceptibility in the Dutch cohort. Similarly to the 
Swedish cohort, these SNPs showed higher minor allelic frequencies in female patients 
Table 3 Haplotype frequencies of PTGES variations in female patients with RA and female controls 
from the Swedish and the Dutch populations      
Haplotype HF HF, cases HF, controls OR (95% CI) P p*
The Swedish population
CCT All 0.843 0.837 0.854 0.88 (0.76-1.02) 0.09 NS
F 0.842 0.831 0.862 0.78 (0.66-0.93) 0.0066 0.0172
M 0.844 0.851 0.828 1.19 (0.90-1.57) 0.22 NS
TTC All 0.130 0.137 0.117 1.19 (1.01-1.40) 0.03 NS
F 0.128 0.139 0.107 1.34 (1.11-1.63) 0.0030 0.0077
M 0.136 0.131 0.146 0.88 (0.65-1.18) 0.39 NS
TCT All 0.011 0.011 0.011 0.93 (0.56-1.57) 0.75 NS
F 0.012 0.012 0.013 0.97 (0.55-1.71) 0.86 NS
M 0.005 0.004 0.007 0.54 (0.16-1.8) 0.30 NS
The Dutch populations
CCT All 0.835 0.836 0.834 1.01 (0.85-1.20) 0.83 NS
F 0.844 0.841 0.855 0.89 (0.65-1.24) 0.50 NS
M 0.827 0.826 0.827 0.99 (0.78-1.25) 0.97 NS
TTC All 0.126 0.128 0.125 1.01 (0.84-1.23) 0.82 NS
F 0.12 0.125 0.105 1.21 (0.84-1.75) 0.29 NS
M 0.131 0.132 0.131 1.00 (0.77-1.30) 0.97 NS
TCT All 0.02 0.018 0.025 0.16 (0.46-1.13) 0.13 NS
F 0.02 0.019 0.021 0.90 (0.40-2.00) 0.80 NS
M 0.02 0.015 0.025 0.61 (0.31-1.19) 0.14 NS
Abbreviations: NS, not significant; HF, haplotype frequency; F, females; M, males. Haplotypes are 
based on PTGES SNPs rs10988484, rs11999368 and rs16931419 and are considered only with the 
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with RA compared with the frequencies in female controls, though the difference was not 
statistically significant (Table 2). In the same way, the frequency of the susceptible haplo-
type TTC was higher in women with RA than in women without RA, though the difference 
was not significant (Table 3). The allelic frequencies among female controls in the two 
populations were identical, whereas the haplotype frequencies were highly similar.
Genetic variations with low or moderate effects on disease susceptibility may not be evident 
in an individual study owing to low statistical power. Thus, we performed a meta-analysis 
combining our results from the Swedish and the Dutch cohorts to verify the significance of 
PTGES polymorphisms for susceptibility to RA. Test for the heterogeneity between EIRA 
and EAC showed no significant differences (P>0.05). The overall statistical power in the 
combined analysis was >80% (in two-tailed test) to detect associations with OR ≥ 1.3, 
given the prevalence of studied genetic factors. The meta-analysis demonstrated a statisti-
cally significant association between the susceptible haplotype TTC and risk of developing 
RA in women with an overall OR of 1.31 (95% CI 1.11-1.56) and P = 0.002 (Figure 2).
PTGES polymorphisms and age of onset and activity of RA
RA is a heterogeneous syndrome with relatively broad variations in disease onset and ac-
tivity. Therefore, we tested the correlation between these parameters and PTGES genetic 
markers in patients from EIRA. Baseline DAS28 and mPGES-1 expression in RA synovial 
tissue were used as disease activity measures.
Cases Controls Odds Ratio






Weight M-H, Fixed, (95%CI)
Sweden 388 2792 0.139 163 1520 0.107 76.8% 1.34 (1.11 -1.63)
The Netherlands 171 1368 0.125 40 380 0.105 23.2% 1.21 (0.84-1.75)
Total (95%CI) 559 4160 0.134 203 1900 0.107 100.0% 1.31 (1.11-1.56)
Test for heterogeneity: X2 = 0.23, df = 1 (P = 0.63), I2 = 0% 
Test for overall effect: Z = 3.11 (P = 0.002)  
0.7            1    1.5    2.0
OR
Figure 2 The association of haplotype TTC with susceptibility to rheumatoid arthritis in women in two 
study populations and the meta-analysis. The squares represent odds ratios (ORs) and lines repre-




There was no association of RA risk haplotype TTC with baseline DAS28 scores or age of 
disease onset in women or men. The minor allele of the SNP rs10739757 corresponded to 
3 years earlier onset of RA in female patients (median 51, range 19-74 vs median 54, range 
16-82, P = 0.0065) (Table 4).
 
Furthermore, we observed that the homozygous major allele in the SNP rs4837404 was 
associated with higher DAS28 scores in women with RA (median 5.57, range 1.74-8.89, vs 
median 5.28, range 1.57-8.29, P = 0.0080), but not in men. In addition, the minor allele in 
the SNP rs2302821 showed a trend toward association with higher DAS28 scores in women 
with RA (median 5.57, range 2.39-8.89 vs median 5.31, range 1.57-8.37, P = 0.0321). Also, 
the female RA patients carrying the minor allele of the SNP rs11792431 showed a trend to-
ward higher DAS28 scores (median 5.63, range 3.82-8.89 vs median 5.32, range 1.57-8.66, 
P = 0.0369) (Table 4). All mentioned variations related to disease course were in low linkage 
disequilibrium (r2<0.34) with SNPs included in the susceptibility haplotype TTC.
Using immunohistochemical analysis, we evaluated the expression of mPGES-1 in RA sy-
novial tissue in relation to PTGES genotypes. There was no difference in mPGES-1 expres-
sion in relation to RA risk haplotype TTC. mPGES-1 expression was significantly higher in 
RA synovial tissue from patients (mean ± SD age, 52.8 ± 14.4 years) carrying the minor 
allele C in SNP rs2302821 compared with the patients (mean ± SD age, 54.4 ± 14.1 years) 
who did not carry that allele (median 12.9% of the stained area, range 8.1-23.6 vs me-
dian 7.1%, range 0.9-10.5, P<0.001, n=9 and 15, respectively) (Figure 3). No differences 
were observed in mPGES-1 expression in relation to gender or treatment of patients with 
NSAIDs, MTX or prednisolone.
dIscussIon
The present study demonstrates the association of variations in the PTGES gene, encod-
ing mPGES-1, with susceptibility to RA in women. The data are consistent for single SNPs 
Table 4 Association of PTGES genotypes with disease onset and activity in female patients with RA 
Disease parameters SNP Genotype Median (range) Counts P -value
Disease onset, years rs10739757 C 51 (19-74) 246 0.0065
TT 54 (16-82) 1136
DAS28, score rs4837404 AA 5.57 (1.74-8.89) 266 0.0080
G 5.28 (1.57-8.29) 321
DAS28, score rs2302821 C 5.57 (2.39-8.89) 114 0.0321
AA 5.31 (1.57-8.37) 491
DAS28, score rs11792431 A 5.63 (3.82-8.89) 63 0.0369
GG 5.32 (1.57-8.66) 536
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and haplotypes in the large study from Sweden. Moreover, the finding was substantiated 
by a meta-analysis of data from the EIRA and Leiden EAC studies. We also found that the 
PTGES genotypes are likely to be related to earlier disease onset and disease severity, as 
they were associated with higher baseline disease activity scores and related to higher 
expression of mPGES-1 in synovial tissue biopsies from RA patients.
PGE2 is actively involved in the regulation of immune response, inflammation and pain, and 
polymorphisms in the genes in the PGE2 biosynthetic pathway are important risk factors for 
cardiovascular, neoplastic and inflammatory diseases6,23. The role of gene polymorphisms in 
the PGE2 pathway in relation to RA risk and severity is less investigated. Two case-control 
studies have revealed a possible protective influence of COX-2 - 765C allele on the suscep-
tibility to RA and disease activity24,25. To our knowledge, the present study is the first one to 
examine an association between PTGES polymorphisms and the risk of developing RA.
We performed an association study in two independent populations. In a large sample from 
Sweden, we found the association between three SNPs from the same recombination block, 
which spread approximately within 9 kb downstream to PTGES, and RA risk in women. This 
significant association was apparent for the SNP rs16931419 (3kb downstream to PTGES) 
after 1,000,000 permutations. Moreover, the TTC haplotype based on the SNPs from this 
recombination block demonstrated a significant association with RA risk in women in the 
Swedish population. We expanded the analysis by including 14 SNPs in the PTGES locus 
and intergenic areas with the PRPX2 or the TOR1B genes to exclude possible association 
with neighboring genes. No evidence for the association between the SNPs in proximity to 
the PRPX2 and the TOR1B genes and RA risk was seen in our study population.
In order to replicate our finding, we analyzed the association between three PTGES SNPs 
included in the haplotype and risk of RA in a Dutch cohort. Though the respective case-
 
 
Figure 3 The expression of mPGES-1 in synovial tissue of RA patients in relation to PTGES genotypes. 
Photographs illustrating brown immunoperoxidase staining of mPGES-1-positive cells in representative 
synovial tissue sections from RA patients. (a) Sample carrying the minor allele C in SNP rs2302821; (b) 
sample that did not carry that allele, counterstained with hematoxylin (original magnification x250). 
Figure 3 The expression of mPGES-1 in synovial tissue of RA patients in relation to PTGES geno-
types. Photographs illustrating brown immunoperoxidase staining of mPGES-1-positive cells in 
represent ive synovial tissue s ctions from RA pat ents. (a) Sample carrying the min r allele C in 





control frequencies had a similar pattern in RA females from Leiden EAC as in EIRA, there 
was no significant association between single SNPs or haplotype and susceptibility to RA 
in the Dutch cohort. The power of the replication study was though limited by the small size 
of the female control group. To increase the power of the study, we performed a meta-anal-
ysis of the data from EIRA and Leiden EAC studies and confirmed the association between 
TTC haplotype and increased risk to RA in women. This finding substantiates the evidence 
that PTGES polymorphisms might be important for susceptibility to RA in women.
The revealed genetic association was consistent for women but not detected for men. The 
higher prevalence of RA in women suggests that genetic risk of RA might vary with sex. 
Indeed, there are a number of associations that show genetic effects in only one sex, or 
reciprocal effects on risk of RA in males and females26,27. Thus, there is strong association 
of SNP rs2900180 in the TRAF-C5 locus with RA without obvious evidence of an effect in 
males27. Also, SNP rs11761231 has been reported in a large study to be associated with 
RA in females, but has no effect on disease status in males26. On the other hand, several 
SNPs in NCF4 (rs729749), NCF2 (rs789181) and RAC2 (rs1476002) genes were found to 
be mildly associated with RA only in men28.
Moreover, the association of COX-2 polymorphisms with disease risk and response to 
NSAID varies between sexes,29,30 most likely as a result of sexual dimorphism in PGE2 
metabolism. Systemic biosynthesis of PGE2 differs markedly between males and females 
in human, as in mice31,32. In rodents, variations in COX-2 and mPGES-1 expression at basal 
and pathological conditions33,34 and different patterns of EP receptor expression35 have 
been reported in females and males. Thus, sex-dependent association of PTGES poly-
morphisms with RA susceptibility may reflect different response to this genetic trigger in 
females and males owing to differences in PGE2 metabolism. However, the absence of an 
association between PTGES polymorphism and RA risk in men might also reflect the small 
number of individuals and low study power, which needs further validation.
The SNPs associated with RA are in a single linkage disequilibrium block and located 
downstream to the 3’ untranslated region (3’UTR) of the PTGES gene. 3’UTR is involved 
in post-transcriptional gene regulation via mRNA stability, the mechanism for which is re-
vealed in the regulation of mouse Ptges gene expression36. These SNPs may be regulatory 
or in linkage disequilibrium with other regulatory polymorphisms in 3’UTR that could simi-
larly modulate the human mPGES-1 expression and predispose individuals to RA.
In our study, we found that gene polymorphisms in PTGES might have not only a disease-
predisposing impact but also a disease¬modifying effect, as two SNPs within PTGES gene 
were related to early disease onset or baseline DAS28 scores. Revealing the relations be-
tween genetic variations and certain functions or phenotypes is currently the most chal-
lenging task for the genetics of complex diseases. We investigated whether gene variations 
associated with disease activity could relate to mPGES-1 expression. We previously dem-
onstrated the expression of mPGES-1 in synovial biopsies as a reliable parameter of inflam-
matory activity in RA. Our data from the current study indicate that mPGES-1 expression 




Association of PTGES with inflammation in RA
with the clinical measure of baseline DAS28. Individuals with the minor allele C in PTGES 
rs2302821 that showed a trend toward association with higher DAS28 had significantly 
higher mPGES-1 expression in RA synovial tissue, which represents additional phenotypic 
replication for this association. Although the total patient number in our experiment is small, 
it represents a unique collection of tissue samples from RA patients with distinct genotypes.
conclusIon
In conclusion, we provide the first evidence that PTGES gene polymorphisms are associ-
ated with susceptibility to RA in women. In addition, PTGES polymorphisms were related 
to earlier disease onset, higher baseline disease activity scores and might contribute to 
higher expression of mPGES-1 in synovial tissue biopsies from RA patients. These data 
suggest the importance of PTGES gene variants in the assessment of RA risk and severity.
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Rodent models for arthritis implicate a role for complement in disease development and 
progression. In humans, complement deposition has been observed in inflamed synovia 
of rheumatoid arthritis (RA) patients. In this study we analysed whether genetic variants of 
complement component C1q predispose to RA.
Methods
We genotyped single nucleotide polymorphisms (SNPs) in and around the C1q genes, 
C1qA, C1qB and C1qC, in a Dutch set of 845 RA cases and 1046 controls. Replication was 
sought in a sample set from North America (868 cases/1193 controls), and a meta-analysis 
was performed in a combined samples set of 8000 cases and 23 262 controls of European 
descent. We determined C1q serum levels in relation to C1q genotypes.
Results
In the discovery phase, five of the 13 SNPs tested in the C1q genes showed a significant 
association with RA. Additional analysis of the genomic area around the C1q genes re-
vealed that the strongest associating SNPs were confined to the C1q locus. Within the 
C1q locus we observed no additional signal independent of the strongest associating SNP, 
rs292001 [odds ratio (OR) = 0-72 (0.58-0.88), P = 0.0006]. The variants of this SNP were 
associated with different C1q serum levels in healthy controls (P = 0.006). Interestingly, this 
SNP was also associated significantly in genome-wide association studies (GWAS) from 
the North American Rheumatoid Arthritis Consortium study, confirming the association 
with RA [OR = 0.83 (0.69-1.00), P = 0.043]. Combined analysis, including integrated data 
from six GWAS studies, provides support for the genetic association.
Conclusion





Genetic association of C1q with RA
InTroducTIon
The recognition molecule of the classical pathway (CP) of complement, C1q, is essential in 
the initiation of the CP following its binding to ligands such as immune complexes1, apop-
totic cells2 and C-reactive protein3. Initially, complement was thought to be involved only in 
innate immunity against pathogens. However, over the last decades a wealth of insight has 
been generated, showing that complement is also involved in many other processes, such 
as coagulation, tissue regeneration, clearance of dead cells and regulation of the adaptive 
immune system1.
C1q is part of the C1 complex, which consists of one C1q molecule, two C1r and two C1s 
serine protease proenzymes4. Conformational changes in the C1q molecule induced by 
binding to one of its ligands result in the release of these enzymes4. Next to its traditional 
ligands such as immunoglobulin (Ig)G and IgM, C1q can also bind to dead cells, DNA and 
matrix components5-7. Structurally the C1q molecule (460 kDa) is composed of 18 poly-
peptide chains (6A, 6B and 6C). The A, B and C chains each have a short N-terminal re-
gion, followed by a collagen region (CLR) and a C-terminal globular region (gC1q domain). 
Three such structural units form the hexameric C1q molecule, that has a tulip-like structure 
via strong non-covalent bonds in the fibril-like central portion4. In contrast to most other 
complement factors, C1q is not made by hepatocytes, but by macrophages and imma-
ture dendritic cells8,9. Following their maturation, dendritic cells shut down C1q production 
completely8,9, which is suggestive of a role in adaptive immune responses10. Indeed, a role 
for C1q in adaptive immunity can also be concluded from in-vivo studies regarding antigen 
presentation11 and cellular activation12-16.
Complete genetic deficiency of C1q is associated strongly with the development of sys-
temic lupus erythematosus (SLE)17. Similarly, several studies, although small, have impli-
cated C1q in the emergence of SLE, as several genetic variants located in the C1q region 
seem to associate with this disease18-22. In addition, two small studies indicated an effect 
of genetic variants of C1q on the progression of cancer and the efficacy of rituximab treat-
ment for lymphoma23,24.
These studies, and the observation that complement deposits are found in the rheumatoid 
arthritis (RA) synovium25, as well as the described correlation between disease activity with 
the presence of activated complement fragments bound to C1q in sera of RA patients26, 
point to a possible involvement of C1q in RA pathogenesis.
For these reasons, we studied whether single nucleotide polymorphisms (SNPs) present in 
the C1q region associate with RA, as this could provide further evidence for a role of the 






SNPs have been genotyped in sets of controls and RA patients who met the American Col-
lege of Rheumatology (ACR) 1987 revised criteria for RA. For the Leiden data set we anal-
ysed 845 RA patients who were recruited from hospitals in the western part of the Nether-
lands. As healthy controls, 1046 subjects were selected randomly by Immunogenetics and 
Transplantation Immunology section of the Leiden University Medical Center. These patient 
and control sets, as well as the patient characteristics, have been described previously27. 
Within this cohorts we obtained a statistical power of 0.7 to detect differences, with a P < 
0.0038 for SNPs with a minor allele frequency of 0.20.
Replication sample sets consisted of (1) the North American Rheumatoid Arthritis Consor-
tium (NARAC)28, that comprised 868 patients and 1193 controls; (2) 277 RA patients and 
387 healthy controls from Crete, Greece, the initial collection of these patients and controls 
has been described previously29; (3) samples from the Genomics Collaborative, Inc. (GCI; 
Cambridge, MA, USA), comprising 475 rheumatoid factor (RF)-positive RA patients and 
475 individually matched controls from the United States, which has been described in 
detail elsewhere30; and (4) data from six genome-wide association studies (GWAS) com-
prising 5539 patients and 20 169 controls31. A summary of the demographic details of the 
cohorts used is provided in Table 1. All patients and controls gave their informed consent 
to participate in the study and the study was approved by the local ethics committee of the 
participating hospitals.
Genotyping methods
For the initial screening we selected tagging SNPs using Tagger32 from HapMap Release II 
CEU data within a 54 kb region encompassing C1qA, C1qB and C1qC, with an R2 < 0-8, 
LOD score [logarithm (base 10) of odds] threshold = 3 and minor allele frequency (MAF) > 
10%33,34. Genotyping of SNPs in the Dutch and Greek sample sets was performed using 
MassArray matrix- assisted laser absorption ionization time-of-flight mass spectrometry, 
according to the manufacturer’s protocol (Sequenom, San Diego, CA, USA). At least 10% 
of the genotypes were assessed in duplicate, with an error rate of <1%.
The GWAS were run using different platforms, as described previously31. If the SNP of inter-
est was not typed in a particular GWAS, then genotype imputation was performed using 
IMPUTE version 2 with the proposed default parameters35. Data were adjusted for popula-
tion stratification, as described elsewhere35.
Detection of circulating C1q levels
To analyse the effect of the different C1q genotypes on circulating levels of C1q we deter-
mined C1q levels in serum of 266 healthy controls by enzyme-linked immunosorbent assay 
(ELISA). We chose to use healthy controls to exclude potential C1q consumption due to 
disease activity in RA patients. The ELISA was performed essentially as described previ-
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specific rabbit anti-human C1q antibody in coating buffer (100 mM Na2CO3/NaHCO3, 
pH 9-6) for 2 h at 37°C. A blocking step was performed using 3% bovine serum albumin 
(BSA) in phosphate-buffered saline (PBS) for 1 h at 37°C. Highly purified serum C1q was 
used as a standard. After adding samples and incubating for 1 h at 37°C, purified rabbit 
IgG anti-human C1q-labelled with digoxigenin (DIG) (Boehringer Mannheim, Mannheim, 
Germany) was used for 1 h at 37°C, followed by horseradish peroxidase (HRP)-conjugated 
Fab anti-DIG (Boehringer Mannheim) for 1 h at 37°C; all these steps were performed in 
ELISA buffer (PBS, 1% BSA, 0-05% Tween 20). Each step was followed by three washes 
with PBS/0-05% Tween 20. Enzyme activity was assessed by the addition of 2,2’-azino-
bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS) (Sigma, St Louis, MO, USA) and H2O2. 
The absorbance at 415 nm was measured using a microplate biokinetics reader (EL312e; 
Bio-Tek Instruments, Winooski, VT, USA), as described previously36.
Statistical analysis
Association of SNPs with RA was performed using a c2 test with one degree of freedom 
or a logistic regression. Odds ratios (OR) and 95% confidence intervals (95% CI) were 
calculated using the Statcalc module of Epi Info Software (Centers for Disease Control 
and Prevention, Atlanta, GA, USA). P-values less than 0.05 were considered significant 
and genotype frequencies in controls did not deviate from Hardy-Weinberg equilibrium at a 
significance level of P < 0.05. Bonferroni correction for multiple testing was applied in the 
discovery phase.
Combined analysis of the genotypes of all studies was performed using a random-effects 
meta-analysis on the estimated effect sizes (log OR) and their standard error. The test for 
heterogeneity was not statistically significant (P = 0.1).
Conditional analysis
To distinguish independent effects in the region we performed an adjusted analysis for 
associations with RA. In order to adjust the effect of rs292001 with effects of other SNPs 
in the region, we compared a two-locus model with rs292001 and each of the other SNPs 
with the model including rs292001 alone, using a likelihood ratio test. The likelihood ratio 
tests were based on the comparison of two generalized linear models. We chose a reces-
sive model for rs292001 based on the data of the discovery cohort and an additive model 
for other SNPs, as no prior information was available.
Sliding window-based haplotype analysis 
In order to analyse which haplotypes would confer most risk, the SNPs used in this study 
were subjected to a sliding window-based haplotype analysis. Adjacent groups of SNPs 
of sizes 2, 3 and 4 were analysed using a generalized linear model. The function haplo.
cc of the R-package haplo.stats was used with the simulation option to obtain empirical 
P-values. Rare haplotypes were grouped together using the default of minimally five ex-





Global P-values for genetic association with RA were obtained by applying the tail-strength 
statistics to P-values from individual SNP associations and permuting phenotype status 5 
x 103 in order to obtain empirical P-values37. Permutation was necessary, as P-values were 
not independent due to linkage disequilibrium between SNPs.
Correction for population stratification
Effect sizes and P-values for the NARAC data set were corrected by a stringent inflation 
factor of 1.3 prior to performing a meta-analysis or the tail-strength measure used for com-
puting global P-values. No other data set showed significant inflation factors and therefore 




Genetic variants in the C1q genes predispose to RA
We first analysed whether genetic variants in the genes encoding C1q (C1qA, C1qB and 
C1qC) are a risk for the development of RA in the Dutch population. For this purpose we 
genotyped a set of 13 tagging SNPs in a discovery cohort of 845 RA patients and 1046 
healthy controls from the Leiden area, the Netherlands. SNPs were selected from a 54 kb 
haplotype block on chromosome 1, with an R2 < 0.8, LOD score threshold = 3 and MAF > 
10%. We captured 94% of the variation in this region. In this discovery set we observed a 
Cohort Cases/controls Genetic ancestry RA criteria, autoantibody Use
Leiden EAC 845/1-046 Caucasian/Dutch ACR 1987, unselected Discovery
NARAC- I 868/1-193 Caucasian/USA ACR 1987, CCP+ Replication
Crete 277/387 Caucasian/Cretan ACR 1987, unselected Replication
GCI 475/475 Caucasian/USA ACR 1987, RF+ Replication
WTCCC 1525/10-608 Caucasian/UK ACR 1987, CCP+/RF+ Meta-GWAS*
NARAC- I+III 1769/5551 Caucasian/USA ACR 1987, CCP+ Meta-GWAS
EIRA 1173/1089 Caucasian/Swedish ACR 1987, CCP+ Meta-GWAS
Canada 589/1472 Caucasian/Canada ACR 1987, CCP+ Meta-GWAS
BRASS 483/1449 Caucasian/USA Rheumatologist,* CCP+ Meta-GWAS
Table 1. Study subjects. 
The number of individuals available for analyses is shown for each cohort as well as the genetic an-
cestry, the criteria used to define rheumatoid arthritis (RA), the selection of patients on the basis of 
their autoantibody status and the use of the particular cohorts in this manuscript. *Detailed information 
in references [31,35]. *The diagnosis of RA was made by a board-certified rheumatologist. GWAS: 
genome-wide association studies; BRASS: Brigham and Women’s Rheumatoid Arthritis Sequential 
Study; NARAC: North American Rheumatoid Arthritis Consortium; WTCCC: Well-come Trust Case 
Control Consortium; GCI: Genomics Collaborative, Inc.; Leiden EAC: Leiden early arthritis clinic; EIRA: 
Epidemiologic Investigation of Rheumatoid Arthritis; ACR: American College of Rheumatology; CCP: 




Genetic association of C1q with RA
statistically significant association for five SNPs (Table 2). Four of these five SNPs remained 
significant after Bonferroni correction for multiple testing (P < 0.0038). We observed the 
strongest association when analysing the data using a recessive model. We also analysed 
these data for global significance using a permutation procedure37; this analysis revealed a 
global significance for C1q in the Leiden data set with a P = 0.003.
 
 
Next, we investigated to what extent the signal we observed was limited to the C1q genes, 
and therefore we genotyped an additional 40 SNPs covering a region of 400 kb, including 
the genes EPHA8, EPHB2 and the C1q genes. In this additional analysis we identified two 
additional SNPs in the C1q genes and four SNPs in the EPHA8 region that are associ-
ated significantly with RA (Fig. 1). We used conditional analysis to study whether the ob-
served signals represent one signal or may represent two independent signals. Effect sizes 
(ORs) for rs292001 (0.72 when analysed alone) varied between 0.77 and 0.66 when ef-
fects of other SNPs on RA were taken into account by analysing two-locus models, where 
one SNP was always rs292001. Four SNPs from EPHA8 were significant, most notably 
rs606002, with a P-value of 0.005. Models including EPHA8 SNPs together with rs292001 
could explain the data set significantly more effectively than the model including rs292001 
alone, indicating an independent effect of EPHA8, which is located relatively far away from 
Patients Controls
SNP n 11 12 22 n 11 12 22 OR (95% CI) P
rs186037_AG 826 0-03 0-25 0-72 839 0-02 0-25 0-73 0-95 (0-76-1-19) 0-677
rs158762_AG 834 0-06 0-36 0-58 1023 0-05 0-35 0-6 0-92 (0-76-1-11) 0-386
rs587585_CT 829 0-02 0-26 0-72 1019 0-02 0-24 0-74 0-93 (0-84-1-10) 0-255
rs665691_CG 822 0-20 0-54 0-26 1022 0-19 0-48 0-33 0-71 (0-58-0-88) 0-0006
rs292001_GA 845 0-17 0-52 0-31 979 0-16 0-45 0-39 0-72 (0-58-0-88) 0-0006
rs682658_GT 821 0-25 0-53 0-21 1018 0-22 0-49 0-28 0-68 (0-55-0-85) 0-0009
rs12404537_CT 832 0-04 0-31 0-65 1018 0-04 0-29 0-67 0-92 (0-75-1-12) 0-38
rs294185_AG 820 0-14 0-48 0-38 1023 0-10 0-48 0-42 0-83 (0-68-1-00) 0-047
rs294179_CT 832 0-22 0-53 0-25 1019 0-18 0-51 0-31 0-73 (0-59-0-90) 0-0024
rs17486657_CT 835 0-08 0-40 0-52 837 0-10 0-42 0-48 1-18 (0-97-1-43) 0-09
rs629409_CT 836 0-02 0-28 0-70 834 0-02 0-25 0-73 0-86 (0-69-1-08) 0-168
rs12040131_CG 820 0-05 0-36 0-59 837 0-05 0-33 0-62 0-88 (0-85-1-09) 0-225
rs292007_CT 837 0-15 0-49 0-36 836 0-12 0-48 0-40 0-85 (0-70-1-05) 0-125
A total of 13 SNPs across the C1q genes were genotyped in 845 patients and 1046 Dutch controls 
from the Leiden area. Shown are genotype frequencies, odds ratios (OR), confidence intervals (CI) and 
P-values using the recessive model; 11 represents the minor alleles, 22 represents the major alleles 
and 12 represents the heterozygous state with the minor allele defined with the allele frequencies in the 
controls. The P-values of significantly associating SNPs are shown in bold.
Table 2. Genotypes of 13 single nucleotide polymorphisms (SNPs) across the C1q genes reveal as-




rs292001 in a region with low linkage disequilibrium. This indicates that the observed effect 
in the C1q genes is not mediated via other linked genes, but represents a true effect of the 
C1q genes themselves. We also performed sliding window-based haplotype analysis and 
observed, for a window size of two, nominal P-values < 0.05 for five SNP windows around 
rs209749 and rs521570 in EPHA8 and 10 SNP windows around rs292001. For a window 
size of three a similar pattern is observed, and a window size of four leads to significant as-
sociations only around rs292001. The strongest associations were observed for windows 
starting at rs294179, rs6690827 and rs12404537 for window sizes two, three and four, 
respectively. All these SNPs are, at most, five SNPs away from rs292001 based on physi-
cal ordering of SNPs. Collectively, these data suggest that the main signal is driven by the 
C1q genes, with a small and independent contribution from EPHA8. Within the C1q region 
we did not observe other signals independent from rs292001 and therefore we focused on 
this SNP in further analysis.
Figure 1. Association plots across the genomic area containing EPHA8, C1qA, C1qC, C1qB and 
EPHB2. We calculate the D-prime and R2 between all the single nucleotide polymorphisms (SNPs) 
analysed in this study in the Dutch cohort. Solid horizontal lines indicate the location of the three 
C1q genes as well as EPHA8 and EPHB2. The top part of the figure depicts the P-value of associa-
tion with rheumatoid arthritis (RA) (circles) and with C1q serum levels in healthy controls (squares) 
for each SNP as -log10 P-values. Horizontal lines indicate the P-values of 0.05, 0.01 and 0.001. The 
P-values shown in black are smaller than 0.001; other values are shown in grey.












Genetic association of C1q with RA
Genetic variants in C1q associate with C1q serum levels
We next analysed specifically the impact of the genetic variants of rs292001 on the protein 
levels of C1q. In order to exclude possible effects of disease activity and treatment on C1q 
production and/or consumption we have analysed the circulating levels of C1q in sera from 
266 healthy controls. This analysis revealed a significant correlation between the presence 
of the ‘protective’ rs292001 G-genotype and higher C1q levels in serum (Fig. 2). These data 
indicate that genetic variants in the C1q locus have an impact upon circulating levels of 
C1q, providing a possible explanation as to how genetic variants present in the C1q-region 




Replication of the C1q association
The finding that genetic variants of C1q are associated with C1q protein and mRNA levels 
provided further support for a contribution of C1q to RA. We next confirmed this genetic 
association by independent replication. Similar to our first analysis of the Leiden data set, 
we analysed the 13 SNPs in the NARAC data set for global significance37. In this replication 
data set we observed a global significance (P = 0.036), confirming that in the NARAC data 
set genetic variants in the C1q genes are also associated with RA. Similarly, an OR of 0.83 
(95% CI: 0.69-1.00, P = 0.043) was observed for rs292001.
To further confirm our findings, rs292001 was typed in two additional cohorts, one from 
Crete and one from North America (GCI). The data from these two cohorts consisting of 
269 patients/369 controls and 469 patients/464 controls, respectively, revealed an effect in 
the same direction as observed in the Leiden and NARAC data set, although not significant 
on its own (Table 3). A meta-analysis on these non-imputed data sets confirmed an asso-
ciation between genetic variation at rs292001 and susceptibility to RA (P = 0.0001, OR = 
0.80; 95% CI: 0.72-0.89).
Figure 2. Genetic variants in the C1q genes affect circulating protein levels of C1q. Circulating levels 
of C1q were analysed by enzyme-linked immunosorbent assay (ELISA) in 266 healthy, genotyped 
controls. Data are plotted in relation to their genotype for rs292001 as mg/ml.





















Supportive evidence from GWAS data
As the GWAS data for the RA studies are now publically available, we also further replicat-
ed our findings obtained for rs292001. Unfortunately, most GWAS data sets did not include 
this SNP and have been generated using a variety of genotyping platforms. Therefore, to 
obtain an impression of the effect of rs292001 genotypes, imputation was performed. The 
quality of imputation was different for each GWAS, with imputation scores ranging from 
0.76 to 0.98 (Table 4; mean maximum posterior probability).
Cohort Nationality Patients Controls OR (95% CI) P
AA AG GG n AA AG GG n
Leiden Dutch 0-17 0-52 0-31 845 0-16 0-45 0-39 979 0-72 (0-75-0-88) 0-0006
NARACI USA 0-17 0-46 0-37 868 0-13 0-46 0-41 1193 0-83 (0-69-1-00) 0-043
GCI USA 0-16 0-47 0-37 469 0-15 0-46 0-39 464 0-93 (0-70-1-20) 0-548
Crete Greek 0-11 0-51 0-38 269 0-14 0-46 0-41 369 0-89 (0-64-1-25) 0-502
Meta 0-80 (0-72-0-89) 0-0001
Table 3. Analysis of association with rheumatoid arthritis (RA) in four cohorts of non-imputed geno-
types of C1q single nucleotide polymorphism (SNP) rs292001.
Genotype counts of the non-imputed data for the cohorts from Leiden, North American Rheumatoid 
Arthritis Consortium (NARAC), Genomics Collaborative, Inc. (GCI) and Crete are depicted, including 
odds ratios (OR), confidence intervals (CI) and P-value. Also a meta-analysis was performed on these 
non-imputed data sets.
SNP rs292001
WTCCC NARACI NARAC III EIRA Canada BRASS
Imputation score 0-950 g-1-000 0-766 0-904 0-901 0-976
Z-score 0-44 1-96 1-2 1-76 0-28 -0-82
GG GA AA Meta OR 0-95 (0-91-1-00)
Cases 1961-8 2683-8 890-2 Meta z 1-908
Controls 7489-6 9605-1 3066-6 Meta 2tP 0-0563
Table 4. Meta-analysis of the six genome-wide association studies (GWAS) for rs292001.
The data that are available for rs292001 from the six GWAS are the composite of six individual GWAS, 
some of which used imputation to obtain data for this single nucleotide polymorphism (SNP); data on 
imputation score and Z-score for each study are given as well as the overall genotype counts for cases 
and controls. The imputation score provides information on the quality of imputation and the Z-score 
is indicative of the effect size, with a score > 0 indicating a positive and a score < 0 indicating a nega-
tive effect. BRASS: Brigham and Women’s Rheumatoid Arthritis Sequential Study; EIRA: Epidemio-
logic Investigation of Rheumatoid Arthritis; NARAC: North American Rheumatoid Arthritis Consortium; 
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All Z-scores, except for the Brigham and Women’s Rheumatoid Arthritis Sequential Study 
(BRASS), revealed an effect in the same direction as observed in the Leiden data set. The 
data from these six GWAS studies, combined with the other data sets studied, now ex-
cluding NARAC from the non-imputed cohorts, revealed a small but significant (P = 0.025) 
contribution to the susceptibility of RA (OR = 0.85; 95% CI: 0.73-0.98) when tested using 
a recessive model, as also used for the individual analyses (Fig. 3).
Figure 3. Meta-analysis of all available data for C1q single nucleotide polymorphism (SNP) rs292001. 
Meta-analysis of the genotyped data from Crete, the Genomics Collaborative, Inc. (GCI), Leiden and 
the combined six genome-wide association studies (GWAS) using a random-effects model. Signifi-
cance of the meta-analysis was P = 0.025.
dIscussIon
In the current study, we have obtained evidence that genetic variants of C1q associate 
with the susceptibility for RA. The observation that several of these genetic variants also 
associate with circulating C1q protein levels suggests that differences in C1q quantity are 
involved in the onset of RA. C1q, the initiation molecule of the classical pathway of comple-
ment, can trigger complement activation following binding to its ligands, such as immune 
complexes, matrix molecules and apoptotic cells1,6,38, all conceivable targets in the context 
of RA. Immune complexes, formed, for example, by anti-citrullinated protein antibodies 
(ACPA), can trigger the classical pathway39. However, this would occur after the induction 
of such antibodies40,41, which would put genetic variants of C1q at the effector-phase of 
RA rather than at the onset of RA. We have divided the patient group on the basis of their 
ACPA status and found the effect of C1q genetic variants in both strata, although the P-
values were stronger in the larger ACPA-positive group (data not shown). However, next 
to its role in activation of the complement system, C1q is thought to have a direct effect 
on adaptive immunity and autoimmunity11-15 and as recently suggested on Wnt signalling42.
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point to a role for the cells that produce C1q, predominantly macrophages and immature 
dendritic cells in the onset of RA8,9. These two cell types are well known to be instrumen-
tal in shaping the adaptive immune response43. It is therefore conceivable that the basal 
expression or the induction of enhanced C1q production by these cells would modulate 
differentially the immune response to foreign antigens and possibly also against self-anti-
gens. Dedicated experiments will need to show how C1q, either intracellularly or excreted 
by such cells, impacts upon the adaptive immune response.
None of the SNPs tested in this study or in high LD with rs292001 (1000genomes.org, pilot 
1 data, R2 > 0-8) have an amino acid-changing effect. Therefore, it seems likely that the 
associating SNPs, or SNPs in LD, have an impact upon the basal expression of C1q or on 
its induction following specific triggers. A genetic locus was also identified in the mouse 
that had an impact upon the C1q expression, secretion and autoimmune organ damage44. 
We observed that the rs292001 G allele, which provides protection against development of 
RA, associates with a higher C1q serum concentration. This is in line with earlier observa-
tions in SLE that low C1q levels predispose to autoimmunity44,45. Although we observed an 
association of genetic variants of C1q with circulating levels of C1q, we did not observe an 
effect on the activity of the CP (data not shown), which is in line with the observation that 
not C1q, but rather C2, is the rate-limiting factor of the CP46.
Although complete genetic deficiency of C1q is associated with development of SLE45, it 
is not yet clear to what extent smaller genetic differences such as represented by SNPs 
are also associated with development of autoimmunity18-21. In the case of complete genetic 
C1q deficiency, it is thought that the absence of circulating C1q may have a direct effect 
on autoimmunity because of defective clearance of apoptotic cells47. However, many other 
processes may (in concert) also play a role, e.g. effects on cytokine production48 or Wnt 
signalling42.
The observed association between genetic variants of C1q and RA do not achieve strin-
gent genome-wide significance. Nevertheless, we believe these data are important, as we 
confirmed our observations in the NARAC data set and observed a similar trend in other 
smaller cohorts, as well as the GWAS studies. We also believe that the associations be-
tween genetic variants of C1q with C1q protein levels provide additional support for a true 
association between genetic variants of C1q and RA. It is possible that deep sequencing 
of these genes would provide additional insight and may reveal the truly causal, functional 
variant.
conclusIon
Collectively, our data show that genetic variants in the region of the C1q genes are associ-
ated with the susceptibility for RA, and that this may potentially be explained by an effect 
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The complement system is a key part of the innate immune system and plays an important 
role in the clearance of pathogens and apoptotic cells upon its activation. It is well known 
that both IgG and IgM can activate complement via the classical pathway by binding of 
C1q to the Fc regions of these immunoglobulins. Recent advances have shown that also 
IgA is capable of activating the complement system. Besides, more insight is gained into 
an additional role for antibodies in the activation of both the alternative and the lectin path-
ways. Mouse models have shown that autoantibodies can activate the alternative pathway 
and induce in cell lysis and tissue damage.
Besides the role of antibodies in complement activation, complement may also be a target 
for recognition by antibodies directed against autologous complement components. These 
autoantibodies play a role in several diseases, especially vascular diseases. Understanding 
how antibodies interact with the complement system will allow the manipulation of this in-
teraction to diminish pathological consequences of autoantibodies and optimize the effect 
of therapeutic antibodies.





Complement activation by (auto-) antibodies
InTroducTIon
As part of the innate immune system, complement is important in the clearance of patho-
gens and apoptotic cells. The activation of complement can occur by three different path-
ways, the classical pathway (CP), the lectin pathway (LP) and the alternative pathway (AP). 
All three pathways comprise different components and are activated in different fashions 
but use a common terminal pathway. The CP is activated when C1q interacts with its li-
gands such as immune-complexes (ICs), the LP is activated when MBL or ficolins binds to 
certain carbohydrates and the AP can be activated by spontaneous C3 hydrolysis or via 
properdin, thereby generating C3(H2O) which can bind factor B (fB). Activation of each of 
these pathways generates C3-convertases resulting in activation of the common terminal 
pathway and generating several effector processes, such as chemotaxis by C3a and C5a, 
opsonization by C3b, and lysis by the membrane attack complex (Ricklin et al., 2010). Ad-
ditionally, the complement system provides a critical link to the adaptive immune system 
by serving as an effector arm of the acquired immune system supplementing antibodies. 
Complement activation by this manner is part of the physiologic immune response and 
plays an important role in fighting infections; however, it is not always beneficial and can 
play a role in different debilitating diseases.
In the current review, an overview of complement activation by (auto)antibodies in both 
human and mouse models is given and the role of this process in disease is discussed.
Complement activation by antibodies IgG and IgM
It is well known that antibodies can activate the complement system through activation of 
the classical pathway. However, new insights indicate that antibodies also play a role in 
activating and influencing both the lectin and alternative pathways.
The classical pathway is activated when C1q binds to the Fc portions of immunoglobu-
lins. In humans the different immunoglobulin isotypes differ in their ability to bind C1q and 
cause subsequent activation of the classical pathway. In this respect IgM, IgG1 and IgG3 
are very effective in this, while IgG2 fixes complement relatively poorly and lgG4, IgA, IgD 
and IgE are not capable of activating the classical pathway (Bindon et al., 1988).
Binding of C1q to IgG occurs within the CH2 domain of the immunoglobulin and is sensi-
tive to ionic strength (Duncan and Winter, 1988; Hughes-Jones and Gardner, 1978). The 
C1q binding site is localized to three side chains, namely, Glu 318, Lys 320 and Lys 322. 
These sequence motifs seem highly conserved through evolution and are found on lgGs 
in all species, indicating this binding site to be universal (Burton et al., 1980; Duncan and 
Winter, 1988). However, this motif is also present on the lgG4 isotype, which is not able to 
bind C1q and activate the CP, suggesting that other features in or near the CH2 domain are 
important for C1q binding. lt was shown that the amino acid residue at position 331, which 
is in close proximity to the indicated binding site of C1q, is important for proper binding 
and subsequent activation. Both lgG1 and lgG3 carry a proline residue at this location, in 




important for C1q binding and Asp 417, Glu 418 and Hys 420 are thought to be involved in 
this process. Additionally, proline residues at position 436 seem to be critical for CP activa-
tion. Since the structure of the C1q binding sites between IgG and lgM are not identical, 
it is thought that the recognition structure of C1q may vary between different molecules 
(Miletic and Frank, 1995).
Additionally, comparative analysis has shown that hexameric IgM is ten to twenty times 
more cytolitically active than pentameric lgM, which may be due to a better symmetry of 
the lgM molecule to bind a C1q molecule (Collins et al., 2002; Davis et al., 1988).
Upon binding of C1q to either IgG- or IgM-containing ICs, auto-activation of C1r occurs, 
followed by activation of C1s. This subsequently leads to activation of C4 and C2 and to 
the formation of the CP C3 convertase.
Next to the well known and well studied activation by IgG and IgM of the CP, more re-
cent studies indicate a role for these antibodies in both the AP, as well as in the LP of the 
complement system.
Activation of the LP occurs when mannose-binding lectin (MBL) binds to certain sugar resi-
dues. Upon binding of MBL, MBL-associated serine proteases (MASP-1 and MASP-2) are 
activated, which subsequently leads to activation of C4 and C2, similar to the CP. lmmuno-
globulins are present in the human body in different glycosylated variants and it has been 
shown that MBL can bind especially to antibodies with certain patterns of glycosylation.
lgG contains a single N-linked glycosylation site on each heavy chain of the antibody and 
the glycans that occupy this site vary in the number of terminal galactoses attached to 
them. MBL can bind the lgG-G0 form, in which the glycans lack a terminal galactose resi-
due, but instead have terminal GlcNAc residues. Interaction of one carbohydrate recogni-
tion domain head of the MBL molecule with a glycan is relatively poor and therefore, most 
likely, only transient in serum. However, in immune complexes containing multiple lgG-G0 
glycans, numerous recognition domains of MBL can engage these antibodies, generate 
high avidity interactions and subsequently activate complement through the LP (Arnold et 
al., 2005; Malhotra et al., 1995).
Although lgM has five N-linked glycosylation sites it is not able to bind MBL and activate 
the LP, because the GlcNAc-structures are not exposed when lgM is bound to antigen 
(Arnold et al., 2005).
ln the AP, activation is not necessarily dependent on immunoglobulins and the first comple-
ment components are bypassed in this process. Antibodies however, do play a role and 
influence the activation of this pathway in different ways. IgG heavy chains can bind na-
scent C3b in a covalent manner, thereby enable the generation of C3-convertases on the 
surface of sensitized targets. Additionally, the rate of cleavage of lgG bound C3b by factor 
H and factor l is slowed remarkably, when compared to unbound C3b. This reduced degree 
of cleavage is mainly due to a diminished affinity for factor H and therefore the amplifica-
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has been shown that C3b(2)-lgG complexes in plasma are the major substrate of C3-con-
vertase and properdin provides these complexes with partial protection from inactivation, 
maintaining the amplification loop longer as compared to that of free C3b (Jelezarova and 
Lutz, 1999; Jelezarova et al., 2000).
Complement activation by IgA
Not only in traditional antibody-mediated diseases such as systemic lupus erythemato-
sus (SLE) and poststreptococcal glomerulonephritis, but also in IgA-dominated diseases 
such as primary IgA nephropathy and Henoch Schonlein purpura (Endo et al., 1998, 2000; 
Hisano et al., 2001; Roos et al., 2006), complement has been clearly recognized as a 
component in the inflammatory process. These findings have led to numerous studies 
into mechanisms of complement activation by IgA, revealing that IgA can activate the AP 
(Hiemstra et al., 1987) and LP (Roos et al., 2001 ) but not the CP.
AP activation by IgA has been shown with immobilized IgA purified from human plas-
ma, resulting in activation of complement in a calcium-independent way (Hiemstra et al., 
1987,1988). Moreover, IgA bound to a bacterial surface in an antigen-specific way can 
also mediate activation of C3 (Fasching et al., 2007; Janoff et al., 1999). The mechanism 
of AP activation has not been precisely defined. Most likely it involves stabilization of the 
C3 convertase on the IgA molecule. Since properdin has recently been recognized as a 
recognition molecule of the AP (Spitzer et al., 2007), it cannot be excluded that properdin 
may directly interact with IgA.
IgA-mediated complement activation, both via the AP and via the LP, is a function of poly-
meric but not monomeric IgA (Hiemstra et al., 1987; Roos et al., 2001). Both IgA sub-
classes in the human circulation, IgA1 and IgA2, consist of polymeric and monomeric IgA. 
From circulating human IgA, the majority is IgA1 and generally less than 20% is polymeric. 
Whereas monomeric IgA is a clearly defined molecule, polymeric IgA may consist of differ-
ent molecular complexes which are incompletely defined (Papista et al., 2011).
Purified human polymeric serum IgA has been shown to interact with human MBL result-
ing in activation of the LP (Roos et al., 2001). This interaction involves the lectin domain of 
MBL and likely involves a carbohydrate ligand. Whereas IgG, IgM and IgA2 are glycosyl-
ated via N-linked sugars only, the IgA1 heavy chain also has O-linked glycosylation sites. 
The structure of IgA heavy chain glycans is highly variable and is determined by the cellular 
source of IgA. Glycosylation may be different between secretory IgA and plasma IgA (Royle 
et al., 2003), and between monomeric- and polymeric IgA (Oortwijn et al., 2006). Moreover, 
also components present in polymeric IgA complexes may be (heavily) glycosylated, such 
as J-chain and secretory component (Royle et al., 2003). In secretory IgA, the glycans of 
secretory component mask MBL-binding sites on the IgA heavy chain (Royle et al., 2003). 
Until now, the precise identity of the ligand involved in interaction between MBL and poly-
meric IgA has not been established.
In a recent study from Terai et al. (2006) purified polymeric serum IgA did not bind to MBL 




by these authors, it is impossible to explain this discrepancy, but most likely it is related to 
the isolation procedure.
The pathophysiological significance of the interaction between IgA and MBL is underlined 
by studies in patients with IgA nephropathy. This renal disease is characterized by deposi-
tion of IgA in the mesangial area of the glomerulus, which is accompanied by complement 
activation, activation of the inflammatory cascade, renal injury, and, on the longer term, 
end stage renal disease. Several reports showed deposition of MBL together with IgA in 
the mesangium (Endo et al., 1998, 2000; Hisano et al., 2001; Matsuda et al., 1998; Roos 
et al., 2006). This MBL deposition was associated with deposition of MASP-2 and C4 
(Roos et al., 2006), supporting its role in glomerular complement activation. Moreover, the 
subpopulation of IgA nephropathy patients with mesangial MBL deposition has a more 
severe glomerular disease than IgA nephropathy patients who only showed evidence for 
complement activation via the AP (Roos et al., 2006). These data were confirmed in a later 
study reporting that C4d-positive IgA nephropathy patients have a significantly more rapid 
progression to end-stage renal disease than C4d-negative patients (Espinosa et al., 2009). 
Taken together, complement activation by IgA may support humoral host defense, but, in 
diseased conditions, may also amplify inflammation and tissue injury. There is evidence for 
involvement of the AP and the LP, and not only MBL but also ficolins may be involved (Roos 
et al., 2006). Since MBL deficiency is the most common human complement deficiency, 
this effector function of the IgA immune system differs between individuals. Furthermore, 
given the large variety of molecular forms of human IgA, the molecular interactions are 
complex and need multidisciplinary studies, with respect to the identity of the protein com-
ponents as well as the structure of the glycans on these molecules.
Complement activation by murine autoantibodies
Several mouse models are available in which autoantibodies play a clear role. Using these 
established models it was possible to unravel the complex contribution of complement 
activation into the overall process of tissue damage. Although many informative models 
are available, in this review we have focused on mouse models of rheumatoid arthritis 
(RA), SLE and subepidermal blistering diseases. The role of autoantibodies in complement 
activation in mouse models of auto-immune diseases suggests a prominent and in some 
cases essential role of the AP in their pathogenesis.
Murine models of arthritis
Several auto-antibody-mediated mouse models of arthritis are available to study RA. Ini-
tially, the role of complement in Collagen Induced Arthritis (CIA) was suggested from stud-
ies where mice treated with cobra venom to deplete complement were found to be refrac-
tory to arthritis until their complement levels were restored (Backlund et al., 2002). Two 
additional mouse models have been extensively used to explore the role of complement 
in arthritis: the anti-G6PI (K/B x N) and CAIA (anti-collagen antibody induced) models. 
Interestingly, in the K/B x N model disease develops spontaneously in the offspring of 
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et al., 2002). Disease is dependent on KRN TCR recognition of G6PI (residues 282-294) 
when presented by MHC class II Ag7. It has been shown that G6PI autoantibodies are 
present in these mice and transfer of either serum or affinity-purified G6PI autoantibodies 
will induce arthritis in healthy mice in a lymphocyte independent fashion (Ji et al., 2002; 
Matsumoto et al., 1999). These antibodies act through FcϒIII receptors and C5a (Ji et al., 
2002). Importantly, the AP and not the CP is required for the development of arthritis. Fur-
thermore, in mice it has been shown that anti-G6PI IgG localizes specifically to the joints 
where arthritis occurs and that localization is dependent on mast cells, neutrophils, FcRs, 
and ICs (Mandik-Nayak and Allen, 2005).
Traditional views regarding the role of properdin in the activation of the AP has also been 
changed, since it has now been shown that properdin can bind to target surfaces and 
initiate AP activation (Hourcade, 2006). It was shown that Cfp-/- mice were significantly 
protected from development of arthritis induced by serum transfer from K/B x N mice 
(Kimura et al., 2010).
Complement activation is also critical for the effector phase of arthritis in the CAIA model 
(Hietala et al., 2004). It was demonstrated that have shown, using this model, that the AP 
is necessary and sufficient for the development of arthritis (Banda et al., 2006). Consistent 
with this observation, it was found that fD-/-, C1q-/-/Df-/-, and MBL-/-/Df-/- mice were also 
resistant to CAIA while C1q-/-/MBL-/- were highly susceptible (Banda et al., 2007, 2010a) 
(Fig. 1). Interestingly MASP-1/3-/- mice are resistant to CAIA for these mice only have an 
inactive form of factor D called pro-factor D (pro-Df), and MASP-1 protein is required for 
the cleavage of inactive pro-Df into active factor D (Banda et al., 2010b; Takahashi et al., 
2010). These studies indicate that the AP can be activated by anti-collagen autoantibodies 
directly and independently from the CP and LP.
 
 
Fig. 1. Antibody mediated arthritis is depending on the AP and not the CP or LP. Clinical disease activity of anti-collagen 
type II mAb-induced arthritis in WT and Clq-/-/MBL-/- and Bf-/— C57 BL/6 mice (Banda et al., 2006, 2007). Mice were 
given a mixture of anti-collagen type II mAbs at day 0. All mice were injected with LPS at day 3. The clinical disease activity 
was assessed every day using a 3-point score for each paw with four paws per animal (maximum score of 12). The data 
are expressed as the clinical disease activity scores. (A) WT (solid black circles) (n = 4) and C1q-/-/MBL-/- (empty white 
circles) (n = 4) mice vs. days after the initial injection of the anti-collagen type II mAb mixture. (B) WT (solid black circles) 
(n = 6) and Bf-/- (empty white circles) (n = 6) mice vs. days after the initial injection of the anti-collagen type II mAb 
mixture. These data are represented as mean ± SEM. *All of the p-values for clinical disease activity in Bf-/- mice in 
comparison with WT were statistically significant at p <0.001. 
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About a decade ago it has been reported that anti-citrullinated protein antibodies (ACPA) 
are present in RA patients that can be detected years before disease onset (Rantapaa-
Dahlqvist et al., 2003). ACPA can be of IgG, IgM, IgE or IgA isotype (Schuerwegh et al., 
2010; Verpoort et al., 2006) and recognize proteins that are post-translationally modified 
by the conversion of arginine to citrulline by the enzyme peptidyl arginine deiminase (PAD) 
(Vossenaar et al., 2003). As ACPA are found long before disease onset, it was hypothesized 
that they could be pathogenic. Human ACPA when tested in vitro have the capacity to 
activate the CP and AP but not the LP (Trouw et al., 2009).
Injection of one purified mouse IgM ACPA monoclonal antibody against citrullinated fi-
brinogen was not pathogenic by itself but exacerbated established disease induced by 
anti-collagen antibodies (Kuhn et al., 2006). In another study five monoclonal autoantibod-
ies to citrullinated collagen type (CII), ACC1-5, were generated (Uysal et al., 2009). Two 
of these five autoantibodies, ACCI (IgG2c) and ACC5 (IgM), when injected into B10.RIII 
mice, directly induced arthritis and the severity of disease was increased after the injection 
of LPS. Importantly, another clone, AAC4 (IgG1), did not induce arthritis. However, when 
this AAC4 antibody was mixed with an anti-collagen antibody M2139 (IgG2b) it did cause 
severe arthritis. Since in mice IgG1 does not activate complement while IgG2b is a strong 
activator of complement this may explain the difference between these monoclonal anti-
bodies in inducing arthritis.
Banda et al. (2008) have shown that the AP of complement is capable of initiating C3 acti-
vation induced by ICs of collagen and anti-collagen autoantibodies, and that it requires the 
presence of N-glycans on the IgG. IgG G0 anti-collagen antibodies activated both the CP 
and AP more than the LP. The glycosylation status of IgG has also been implicated in the 
pathogenesis of RA. EndoS, an endoglycosidase isolated from Streptococcus pyogenes, 
specifically cleaves the terminal sialic acid residues from glycan groups and has been used 
extensively in recent years as a tool to modify the glycosylation status of pathogenic anti-
bodies. For one EndoS-treated anti-collagen autoantibody, M2139-IgG2b, it was shown to 
have lost its capacity to induce arthritis in B10.RIII mice (Nandakumar et al., 2007). Inter-
estingly, in these studies EndoS treatment did not affect the binding of anti-collagen anti-
bodies to CII and their capacity to activate complement as there was no difference in C1q 
deposition on anti-collagen antibodies with and without EndoS treatment bound to CII, but 
it reduced IgG binding to FcϒR and the formation of stable ICs (Table 1). Collectively, these 
mouse models show that the AP is essential for tissue damage induced by auto-antibodies.
Murine models of SLE
SLE is an auto-immune disease in which complement plays a prominent role. It is char-
acterized by autoantibody production, immune complex formation, complement activa-
tion and systemic tissue damage. The deposition of ICs in glomeruli of patients with SLE 
causes lupus-nephritis via complement activation, generation of C3a and C5a, and MAC 
formation (Biesecker et al., 1981; Falk et al., 1983; Wyatt et al., 1979). Complement activa-
tion increases clearance of ICs but deposition of complement activation products contrib-
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Antibodies to double-stranded DNA (dsDNA) represent the hall-mark of SLE and their ca-
pacity to fix complement has been associated with disease activity (Mackworth-Young et 
al., 1986; Rothfield and Stollar, 1967). By using antigen microarray technology to analyze 
serum derived from lupus prone MRL/lpr mice it has been shown that C3 deposition on 
nucleic acids is profoundly increased by the presence of mAbs specific for dsDNA (Papp et 
al., 2010). Observational studies have shown that the inflamed glomeruli of MRL-lpr mice 
stain positive for markers of CP, LP and AP activation (Trouw et al., 2004b, 2005). MRL/lpr 
mice lacking either fB or fD developed less renal disease than WT mice (Elliott et al., 2004; 
Watanabe et al., 2000). Auto-antibodies to dsDNA, did not differ between fD+/+, fD+/- and 
fD -/- MRL/lpr mice at any age. Thus lack of AP activation protects against proliferative 
renal disease in MRL/lpr mice. However, C3-/- MRL/lpr mice are not protected from renal 
disease and there is no difference in autoantibody titer compared with WT mice. This in-
dicates that complement activation is not required for the production of auto-antibodies 
in MRL/lpr mice. Nonetheless inhibition of the AP is beneficial in lupus nephritis despite 
glomerular IgG deposition mediated effects. Blocking the AP has profound effects next 
Antibody Disease association
Anti-C1q Hypocomplementaemic Urticarial Vasculitis Syndrome; Felty’s syndrome; SLE; Rheu-
matoid vasculitis; Classic polyarthritis nodosa; Sjogren’s syndrome; Mixed connective 
tissue disease; Polygondritis; Temporal arthritis; Mixed cryoglobulinaemia; MPGN; 





Anti-factor B Dense deposit disease
Anti-factor H MPGN
Anti-C4 SLE




SLE; rheumatoid arthritis; paroxysmal nocturnal hemoglobinuria; chronic liver dis-
ease
Anti-CR1 Colitis; SLE; liver cirrhosis
Anti-CR2 HIV
Anti-CR3 Rheumatoid arthritis; auto-immune neutropenia
Anti-CD46 HIV
Anti-CD59 Multiple sclerosis
Table 1. Overview of auto-antibodies directed towards complement components.
Adapted from (Norsworthy and Davies, 2003; Seelen et al., 2003a; Trouw et al., 2001), with addition 
of anti-H ficolin (Yae et al., 1991), anti-MBL (Seelen et al., 2003b), anti-factor H (Skerka et al., 2009) 




to SLE also in many inflammatory and renal diseases underscoring the generality of this 
pathogenic mechanism (Fung et al., 2001; Kalli et al., 1994; Moore, 1994; Pascual et al., 
1993; Tanhehco et al., 1999). In these mouse models of SLE also anti-C1q autoantibodies 
play a role, which will be discussed in below. 
Murine models of subepidermal blistering disease
Epidermolysis bullosa acquisita (EBA) is an auto-immune disease with chronic subepider-
mal blisters of skin and mucous membranes and is characterized by autoantibodies to 
type VII collagen (COL7) (Lapiere et al., 1993; Woodley et al., 1988). Experimental EBA can 
be induced in mice by injecting rabbit or human anti-mouse COL7 IgG (Sitaru et al., 2006; 
Woodley et al., 2005, 2006). The pathogenic relevance of COL7 auto-antibodies has been 
shown by passively transferring these antibodies in mice and by injecting mice with autolo-
gous COL7 (Sitaru et al., 2006). Anti-COL7 antibodies induced blisters in normal mice but 
failed to induce blisters in C5-deficient mice, supporting the role of complement activation 
in the pathogenesis of EBA. Additionally, using genetic manipulations similar to those de-
scribed above, it has been shown that complement activation by the AP is required to elicit 
disease (Mihai et al., 2007).
Bullous pemphigoid (BP) is another example of an auto-immune subepidermal blistering 
disease (Gudi et al., 2005; Langan et al., 2008). Serum anti-human COL17 autoantibodies 
target human type XVII collagen (Robson et al., 2003). Deposition of anti-human COL17 
auto-antibodies at the basement membrane zone triggers a sequence of inflammatory 
cascades including complement activation, infiltration of neutrophils and eosinphils, and 
degranulation of dermal mast cells (Chen et al., 2001; Liu et al., 2008; Nishie et al., 2007; 
Oikarinen et al., 1983; Robson et al., 2003; Stahle-Backdahl et al., 1994). Recently, an 
anti-hCOL17 IgG1 monoclonal antibody was shown to effectively reproduce a BP-like phe-
notype in mice (Li et al., 2010). Interestingly, a human IgG1 monoclonal antibody, mutated 
at residue P331 in the Fc region, lost its capacity to activate complement and also lost its 
pathogenicity. This is the first report that IgG1 antibodies to hCOL17 can induce blister 
formation in mice and it raises the possibility that an IgG1 monoclonal with an Fc modifica-
tion may be used to block pathogenic epitopes in auto-immune disease (Li et al., 2010).
Although the initiation of the complement activation normally takes place by the CP or by 
the LP, potentially it is the AP amplification that causes most tissue damage. In addition 
the AP itself can be activated by auto-antibodies in the absence of CP and LP to cause 
tissue damage.
Why is the absence of any component of the AP so protective for tissue damage induced 
by autoantibodies? The major part of the pro-inflammatory C5a is generated by the AP 
(Banda et al., 2010a) and each component of the AP uniquely participates in this activation 
process. Whether properdin binds to autoantibodies and initiates AP of the complement is 
a subject of future research.
To what extent this is also true for humans is not clear. One in vitro study, compared the 
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mouse and human sera. The level of C5a generated by the AP alone (79.1%) in mouse 
sera was significantly higher than the level generated by the CP alone (46.6%). However, 
the opposite was observed with human sera (Banda et al., 2010a,b). Also of note is the 
observation that C3 deficient persons can develop SLE, indicating that in the absence of 
complement activation, immunecomplex mediated damage can occur. However, in com-
plement sufficient SLE patients complement activation clearly contributes to damage.
Autoantibodies to complement components
Next to the fact that several complement components like MBL, C1q and Properdin can 
interact with antibodies and result in complement activation, complement itself may be a 
target of autoantibodies (Norsworthy and Davies, 2003; Trouw et al., 2001). In this regard 
the best known autoantibodies are directed against for instance C1q and the amplifica-
tion convertase C3bBb. In this section we provide a very brief overview of autoantibodies 
against complement.
Autoantibodies against several complement components have been described including 
autoantibodies against C1q and MBL(Seelen et al., 2005; Siegert et al., 1991; Trendelen-
burg et al., 1999; Trouw and Daha, 2005). Both of these autoantibodies have been de-
scribed in patients with systemic lupus erythematodus (SLE) but may also be found in 
other diseases. Generally the auto-antibodies are directed against neoepitopes and this is 
evident especially concerning autoantibodies against C1q that react mainly with immune-
complex-bound C1q.
Anti-C1q autoantibodies are present in 30-50% of SLE patients (Monova et al., 2002; Sieg-
ert et al., 1991), and are strongly associated with the development of lupus nephritis. The 
absence of these antibodies seems to exclude active renal disease (Trendelenburg et al., 
1999). However high titers of anti-C1q autoantibodies have also been reported in hypo-
complementaemic urticarial vasculitis syndrome (HUVS), suggesting that there may be a 
contextual element to the deposition of this antibody (Wisnieski and Naff, 1989).
There is strong evidence that anti-C1q autoantibodies may result in direct interaction with 
C1q that is transiently present in the glomerular basement membrane (GBM) leading to 
a low degree of inflammation accompanied by infiltration of polymorphonuclear leuko-
cytes. However for a pronounced induction of renal injury and proteinuria more than one 
hit seems to be required (Trouw et al., 2004a). Anti-C1q autoantibodies are present in many 
strains of auto-immune mice (Hogarth et al., 1996; Trinder et al., 1995). In MRL-lpr mice 
a temporal association between the occurrence of anti-C1q autoantibodies and nephritis 
was observed (Trouw et al., 2004b) whereas in another model of lupus nephritis no such 
correlation was found (Bigler et al., 2010). In search of the involved mechanistics, mice 
were pretreated with a subnephritogenic dose of anti-GBM antibody followed by an in-
jection of anti-C1q, and a complement-dependent glomerular inflammation was induced 
(Trouw et al., 2004a). Mice treated with anti-GBM antibody or anti-C1q antibody alone 
developed no renal disease. Anti-C1q antibodies, were dependent on their antigen C1q, 




antibodies caused no glomerular damage in C4-/-, C3-/- and Fcϒ receptor-deficient mice, 
demonstrating that the mechanism of glomerular damage was dependent on the CP and 
on Fcϒ receptors.
Auto-antibodies against MBL have been described also in patients with SLE (Seelen et 
al., 2003b; Trendelenburg et al., 1999; Trouw and Daha, 2005) but seem to occur only in 
patient that are not deficient for MBL. In SLE patients, MBL deficiency, is associated with 
increased presence of autoantibodies against cardiolipin and against C1q (Seelen et al., 
2005). The hypothesis is that an enhanced presence of autoantibodies may be related to 
disturbed clearance of apoptotic cells due to impaired MBL function.
Several autoantibodies against complement regulators have been reported including au-
toantibodies against factor H and C1-inhibitor. Anti-factor H autoantibodies are strongly 
related with the occurrence of atypical hemolytic uremic syndrome and C3-nephropathies 
(Dragon-Durey et al., 2010a). The presence of anti factor H autoantibodies induces sys-
temic AP activation resulting in low plasma levels of C3 and factor B. The antigenic level 
of factor H may be subnormal but more importantly the binding of these autoantibodies 
causes a functional defect in factor H imparing its capacity to interact with endothelial sur-
faces (Dragon-Durey et al., 2010b). The age at onset of the anti factor H auto-antibodies 
varies between the very young of less than 1 year up to 13 years in age (Dragon-Durey et 
al., 2010a).
The presence of anti-C1-inhibitor autoantibodies is a hallmark of acquired C1-inhibitor de-
ficiency (Donaldson et al., 1996; Meszaros et al., 2010). A recent study in a large cohort of
SLE patients revealed that the level of anti-Cl-inhibitor-autoantibodies was significantly 
higher in SLE patients than in controls, which was associated with disease activity. Ac-
quired Cl-inhibitor deficiency in elderly patients is in most cases associated with clonal B 
cell diseases, most likely due to production of monoclonal antibodies against C1 inhibi-
tor. Several studies have indicated that the anti-Cl-inhibitor-autoantibodies result both in 
inhibition of functional activity of Cl-inhibitor and in reduction in Cl-inhibitor levels and as a 
consequence in deregulation of both the CP and LP.
Two convertases determine the degree of activation of the central component of comple-
ment C3. These are the CP/LP induced C3-convertase C4b2a and the amplification con-
vertase C3bBb. Autoantibodies against C4b2a (C4NeF) were described in patients with 
SLE (Daha et al., l980; Gigli et al., l985) and shown to functionally stabilize the otherwise 
labile enzyme resulting in enhanced activation of C3, low levels of C3 and potentially in 
inflammation. Unfortunately C4NeF had received little attention in later years.
An activity present in serum of patients with membranoproliferative glomerulonephritis 
(MPGN) that was able to induce activation of complement in normal human serum via the 
AP was recognized for the first time by West et al. (l965) in the early sixties. This activity 
was indicated as C3-nephritic factor (C3NeF). Since then C3NeF has received broad atten-
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it stabilizes the otherwise labile C3bBb convertase giving it a longer half-life and thereby 
the potential to activate more C3 resulting in reduced circulating levels of C3. C3NeF is 
highly associated with the occurrence of MPGN. Stabilization of the C3bBb convertase 
can also occur by Properdin (Fearon and Austen, l975) but there is a main difference be-
tween Properdin and C3NeF. While the stabilization by C3NeF gives a biphasic decay 
characteristic of the C3bBb convertase sites (Daha et al., l976), the Properdin stabilizati-
on results in a linear decay pattern. This suggests that C3NeF only stabilizes the C3bBb 
convertase sites to which it is bound while Properdin seems to interact with all convertase 
sites dependent on the concentration of properdin used and presumably by moving from 
one site to another.
Results obtained with a large number of C3NeF preparations suggest that C3NeF is an 
auto-antibody directed against antigenic determinants on Bb, which are exposed after 
interaction of B with C3b (Daha and Van Es, l98l). Taken together C3NeF seems to be 
responsible for hyper catabolism of C3 with the consequence that activated C3 is depo-
sited in the kidney resulting subsequently in injury to the kidney. One study provided the 
proof-of-concept showing that three mouse IgM monoclonal antibodies had C3Nef-like 
activity (Daha et al., l984). More recent studies indicate that several mechanisms including 
deregulation of convertase function as can be seen in patients with atypical hemolytic 
syndrome, gain of function mutations in C3 and B, or the occurrence of anti-H and anti-B 
auto-antibodies are all associated with hypercatabolism of C3 and induction of vascular 
injury (Skerka et al., 2009).
Therapeutical antibodies and complement activation
With the approval by the US Food and Drug Administration of 28 monoclonal antibodies for 
use in humans in 20ll, these antibodies have become a critical component of clinical treat-
ment regimens in a large variety of indications. Many therapeutic monoclonal antibodies 
exert their killing activity through several mechanisms of action. Whereas several antibod-
ies kill via apoptosis, receptor down modulation or by altering signal transduction, others 
use the immune system to induce efficient killing of target cells. Indeed, successful thera-
peutic antibodies like alemtuzumab and rituximab seem to be well able to eradicate tar-
get cells via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent 
cytotoxicity (CDC) (Teeling et al., 2004, 2006; Waldmann and Hale, 2005). Alemtuzumab 
targets CD52 on B- and T-cell cancers, while rituximab targets CD20 on B-cells and is used 
in the treatment of many lymphomas, leukemias, transplant rejection and some autoim-
mune disorders (Olszewski and Grossbard, 2004). A large body of evidence supports the 
role of complement activation in antibody immunotherapy in patients (Cragg et al., 2003; Di 
Gaetano et al., 2003; Golay et al., 2000, 2006; Idusogie et al., 2000; Manches et al., 2003; 
Reff et al., l994; Zent et al., 2008). Furthermore, under certain complement limiting condi-
tions, rituximab can become ineffective (Glennie et al., 2007; Taylor and Lindorfer, 2008). 
Fresh frozen plasma could enhance or restore complement titers and rituximab therapy in 
CLL patients, which was probably due to the exhaustion of the limiting factor C2 (Kennedy 




The role of complement in immunotherapy is further supported by the observation that 
polymorphisms in C1q were associated with response rates to rituximab treatment in fol-
licular lymphoma (Racila et al., 2008).
The fact that therapeutic monoclonal antibodies are able to use the complement system 
to induce target cell killing is intriguing. First of all, they need to overcome the inhibitory 
effects of a set of plasma proteins and membrane-bound complement regulatory proteins, 
which prevent unintended injury by our own activated complement (Atkinson et al., l99l; 
Junnikkala et al., 2000; Kim and Song, 2006; Kirkitadze et al., l999; Liszewski and Atkin-
son, l996; Morgan et al., l998). Especially tumor cells, in comparison to normal cells, can 
be difficult to kill since complement inhibitors may be upregulated such as via cytokines, 
streamers or be the result of selection (Beum et al., 2008; Blok et al., 2003; Cruz et al., 
2007; Teeling et al., 2004).
Secondly, binding to very small or compact surface proteins, like CD20, CD52 and CD38 
seems to be a prerequisite for killing via CDC (de Weers et al., 20ll; Polyak et al., l998; Xia 
et al., l993). Possibly, binding close to the cell surface facilitates effective capture and 
concentration of active complement components proximating to the cell membrane, po-
tentially shielding activated complement components (C4 and C3) from inactivation by 
fluid phase inhibitors, overcoming inhibition by mCRPs and promoting efficient generation 
of the MAC complex (Beum et al., 2008; Bindon et al., l988; Michaelsen et al., l990). This 
is further exemplified by atumumab that binds an epitope encompassing both the small 
and large loop on the CD20 molecule very close to the cell membrane, which results in 
killing of B cells with low CD20 densities, and reduced sensitivity to complement inhibi-
tors (Beum et al., 2008; Pawluczkowycz et al., 2009; Teeling et al., 2004, 2006). Also other 
factors, like binding avidity to C1q and clustering of surface antigens into lipid rafts may 
further influence CDC and subsequent therapeutic activity (Cragg et al., 2003; Mone et al., 
2006; Pawluczkowycz et al., 2009; Taylor and Lindorfer, 20l0; Teeling et al., 2006; Wierda 
et al., 20l0).
Recent work has shed light on the role of complement factors, C1q, and C3 in opsonization 
of target cells (Gelderman et al., 2004; Racila et al., 2008). A split product of the initiation 
of the MAC complex, C5a, is thought to contribute to the complement mechanism of ac-
tion. C5a is a potent chemoattractant, stimulator and survival factor of effector cells which 
are involved in the elimination of malignant cells (Monk et al., l994; Perianayagam et al., 
2002). It also modulates IgG Fc receptor expression via upregulation of activating and 
downregulation of inhibitory IgG Fc receptors (Shushakova et al., 2002). By using fusion 
proteins containing C5a, enhanced ADCC of breast cancer cells was shown (Fuenmayor 
et al., 20l0).The importance ofCR3 in tumor cell killing was underscored by Boross et al. 
(20ll) who recently showed that antibodies can kill tumor cells in vivo after binding of the 
complement receptor CR3 to C3 on target cells.
Recent evidence shows that CDC can be further augmented by conferring more potent 
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generate a variety of chimeric IgG molecules or by amino acid substitutions (Dall’Acqua 
et al., 2006; Idusogie et al., 2001; Michaelsen et al., 2009; Moore et al., 2010; Natsume 
et al., 2009). Optimization of IgG1 antibodies for complement has enormous potential for 
improving the next generation of therapeutic antibodies which could bear great promise to 
increase the chances to cure patients in the future.
conclusIons
Collectively we conclude that antibodies, as a traditional hallmark of adaptive immunity, 
contribute to host protection and to tissue damage by utilizing additional mediators of the 
innate immune system and especially complement activation. All three pathways of com-
plement can be initiated directly by antibodies. However, clearly not all antibodies activate 
each pathway. Different isotypes have a different capacity to trigger complement activa-
tion in vitro. In-vivo however, the relative contribution of each isotype is less clear. Even 
the relatively weak activators may still activate sufficient complement as to result in tissue 
pathology as for instance seen in IgA nephropathy. The molecular composition, sequence, 
density and glycosylation status of the different antibody isotypes determine, to a certain 
extend, their ability to activate each of the pathways. Such modifications provide us with 
the possibility to interfere with the pathogenic effects of autoantibodies and serve as a tool 
for optimization of therapeutic antibodies. Obviously complement activation by antibodies 
is not just bad news, it provides an important effector mechanism to clear pathogens and 
may be used therapeutically to kill tumor cells or autoreactive immune cells.
The fact that autoantibodies not directed against a tissue antigen but rather against a com-
plement factor or a convertase may still induce a tissue specific inflammatory response, 
makes it difficult to dissect the relative contribution of each autoantibody to the overall dis-
ease process. The traditional view that only the CP is directly activated by antibodies and 
that only IgG and IgM can activate complement are both replaced by the concept that all 
pathways of complement can be activated by antibodies directly and that no general rules 
apply to isotypes and or subtypes regarding their in vivo complement activating potential. 
Additionally, once tissue injury has been initiated, the tissue itself, as exemplified by the 
activation of all three pathways by cell debris, may directly contribute to enhanced tissue 
damage.
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Rheumatoid arthritis is a chronic auto-immune disorder, of which persistent synovitis, bone 
erosions and auto-antibody formation are characteristic features[1]. Although the etiology 
of the disease remains largely unknown, it is established that genetic risk factors play a 
pivotal role in disease pathology. Both family and twin studies have shown that the genetic 
contribution to the disease can be estimated around 50%[2-4]. 
The most important genetic risk factor for RA was first described in the 1970’s and is lo-
cated in the HLA region. The associated HLA-DRB1 alleles all encode a similar amino-acid 
sequence at a particular position of the hyper variable region of the HLA class II molecule. 
This finding resulted in the SE hypothesis, in which was proposed that the SE motif is di-
rectly involved in RA pathogenesis. It was postulated that in this binding groove, the HLA 
class II molecule could present a specific arthritogenic peptide to auto-reactive T-cells[5, 
6]. Although it has been shown that epitopes derived from human citrullinated vimentin 
can be recognized by HLA-DRB1*0401 restricted T-cells, the hypothesis still remains to be 
elucidated[7].
After the identification of the HLA-DRB1 alleles, it was not until 2004 that the first non-HLA 
locus that associated with RA susceptibility was identified[8]. Due to advances in genotyp-
ing technologies, which could be performed at reasonable costs, the identification of novel 
genetic risk factors took a flight[9]. 
In the current thesis the genetic contribution of non-HLA genes to RA susceptibility was 
further investigated and the functional relevance of these loci in disease pathology was ex-
plored.
Establishing genetic risk factors
The recent burst in genetic association studies for disease susceptibility has led to the 
identification of many risk loci associated with RA susceptibility. Although part of these 
newly identified loci will truly be associated with RA, part will show to be type I errors, in 
which the associations appear to be false positive findings. To separate the true findings 
from the false positive ones, it is of utmost importance to replicate newly identified genes in 
independent populations of similar origin. In both chapter 2 and chapter 3, such replication 
studies for recently identified genes were performed. 
In chapter 2 three SNPs in STAT4, IL2/IL21 and CTLA4 genes, were investigated in the 
Leiden RA population. Subsequently, a meta-analysis of all publicly available genotype 
data was performed to identify the overall genetic association with RA susceptibility. The 
association with the STAT4 gene was first described in 2007 and replicated consistently in 
several Caucasian and Asian populations[10-12]. The IL2/IL21 region, on the other hand, 
had only been described in one study thus far and the CTLA4 gene had shown inconsis-
tent results in several replication studies[13-16]. In the present study, both the SNPs in 
the STAT4 gene and the CTLA4 gene could be independently replicated in our Dutch RA 
population, while the SNP in the IL2/IL21 region showed a clear trend towards association. 
More importantly, all three loci were further confirmed in a well powered meta-analysis, 





In chapter 3 a replication study of two SNPs located in the interleukin 2 pathway is de-
scribed. A recent GWAS in the WTCCC population had indicated the IL2RA and IL2RB 
regions, located in this pathway, to be novel genetic risk factors for RA[17]. These find-
ings were replicated in our independent Dutch RA population, thereby providing further 
evidence for true association.
Missing heritability
In addition to the in chapter 2 and chapter 3 described loci, currently over 46 genetic re-
gions have been identified as true genetic risk factors with statistically robust associations. 
These associations however, confer relatively small increments in risk and thereby contribut-
ing only marginally to disease susceptibility[9, 18]. It is thought therefore, that a great part of 
the genetic risk for RA has not yet been explained. Even including the HLA region, it is likely 
that more than 50% of the genetic risk for RA remains to be identified. Many explanations 
for this ‘missing heritability’ have been suggested, including structural variants that were 
poorly captured by the existing genotyping arrays, gene-gene interactions and inadequate 
account of the shared environment among relatives. An additional possibility, on which most 
speculations have been focused, is that multiple rare variants contribute to disease risk in a 
significant subset of the RA population. Rare variants in this matter are defined as variants 
with an allele frequency less than 5%, or even less than 1%, but not rarer than 0.5%. Such 
variants are not sufficiently frequent to be captured by the current GWAS arrays, nor do they 
have large enough effect sizes to be identified by linkage analysis in family studies. These 
variants can be identified by resequencing genomes of patients and healthy individuals[19]. 
These low frequency variants will have higher effect sizes than the currently identified non-
HLA risk loci and could thereby contribute substantially to the current ‘missing heritability’. 
Next to the investigation of rare variants, structural variants and gene-gene interactions 
to explore the ‘missing heritability’, additional common variants can be identified by can-
didate gene approach. Although the contribution of these variants to disease risk have 
shown to be marginal and the candidate gene approach has its disadvantages compared 
to GWAS, a candidate gene study might identify a risk factor that has simply not been 
typed or identified in the large scale assays. 
In chapter 5 a study is described, in which common variants located in the VTCN1 re-
gion were investigated for association with RA susceptibility by candidate gene approach. 
VTCN1 encodes a protein, which has been reported to be a negative regulator of T-cell 
responses in vitro by inhibiting proliferation and cytokine production[20, 21]. In RA patients 
the soluble form of the protein is more frequently observed than in healthy individuals and 
is correlated with disease activity as measured by DAS 28[22]. In knock-out mice, the pro-
gression of inflammation in a collagen induced arthritis model was accelerated compared 
to wild type mice[22]. In addition to these functional indications that VTCN1 plays a role 
in RA pathology, genetic studies in juvenile idiopathic arthritis identified this region to as-
sociate with this disease[23]. Since both functional and genetic data indicated a possible 
role of VTCN1 in RA, the genetic contribution to RA susceptibility was investigated by a 




In the discovery phase of this study, a significant association for two SNPs was observed. 
Replication of these findings in two independent populations from northern-European de-
scent, showed an overall significant association for both variants. These data indicate that 
this is a novel genetic risk factor for RA susceptibility, although further replication in inde-
pendent cohorts is necessary to tease apart the role of VTCN1 genetics in RA. 
In chapter 7 another novel genetic risk factor is identified by candidate gene approach. 
In this study the genetic contribution of the C1Q genes was investigated in relation to RA 
susceptibility. As well as in chapter 5, this region was chosen upon strong indications of 
both functional and genetic data.  It was observed that a complete genetic deficiency of 
C1Q is strongly associated with the development of Systemic Lupus Erythematosus[24]. 
Moreover, complement deposits can be found in the synovium of RA patients and a cor-
relation between disease activity and the presence of activated complement fragments 
bound to C1q in sera of RA patients has been described[25, 26]. 
In the Leiden RA population five SNPs in the C1Q genes were significantly associated with 
disease. Subsequent replication of the most significant SNP in three independent popula-
tions supported the initial finding. Additionally, in a meta-analysis of six GWAS, contain-
ing a substantial number of patients and controls, the association was maintained, even 
though with borderline significance. 
Disease subsets
The identification of additional variants, being rare variants, structural variants, gene-gene 
interactions or common variants, will probably lead to the identification of a substantial 
part of the genetic risk conferred to RA. It can be expected however, that part of the ge-
netic background of RA, as described currently, will not be elucidated. RA is a phenotypic 
disease and is defined by use of classification criteria. In these criteria, points are scored 
for certain disease features and an individual is classified as having RA when a minimum 
score is obtained[27]. This results in a heterogeneous disease, with highly variable disease 
outcomes between patients. It can be expected that the current classification embraces 
several disease subgroups, each with their own distinct risk factors and pathophysiology. 
This implies that a more precise definition is needed and further research towards specific 
immunological or other biologic features that distinct subgroups is desired.
To date, a feature that has been shown to identify specific subgroups of the disease is 
ACPA. It is known that, to a certain extent, presence or absence of ACPAs can predict 
disease outcome and these antibodies are one of the best clinical predic tors of radiologi-
cal progression[28]. Moreover, it has been shown that patients with ACPA-negative disease 
are more likely to achieve drug-free remission than those who test positive for these auto-
antibodies[29]. Interestingly, the most prominent genetic risk factor for RA, the HLA shared 
epitope region, predisposes to ACPA positive RA, whereas another haplotype in this re-
gion, HLA-DRB1*03, predisposes to ACPA-negative disease[30, 31]. The majority of loci 
that correlate with RA have, however, been identified in ACPA-positive patient populations, 





studies have suggested a role for IRF5 and genes encoding C-type lectin-like receptors in 
ACPA-negative disease, and, in chapter 2 of this thesis, it was shown that a polymorphism 
of STAT4 is associated with both disease subsets, whereas a variant of CTLA4 is associ-
ated with ACPA-positive RA only[33, 34]. Together, these studies reveal that ACPA-positive 
and ACPA-negative RA have different genetic association patterns.
To gain further insight into these association patterns, a genome-wide association study in 
ACPA-positive and ACPA-negative patient populations was performed recently[35]. More 
than 1.7 million SNPs were studied for association with disease, in 774 ACPA-negative 
and 1,147 ACPA-positive patients with RA. The ACPA-positive find ings were subsequently 
replicated in two RA cohorts of Western European descent. When the ACPA-positive sub-
set was compared with the ACPA-negative subset, genome-wide significant differences 
between the two groups (P <2.9 × 10–8) could be estab lished for several SNPs within the 
HLA region. No significant associations of loci located outside the HLA region could be 
identified, which is likely to be due to the insufficient power provided by the relatively small 
ACPA-negative study population. Nonetheless, these data support the idea that genetic 
backgrounds contribute differently to the two RA disease subsets characterized by ACPA 
status. Expansion of the ACPA-negative study population is needed to eluci date the ge-
netic contribution of loci outside the HLA region. 
The data of Padyukov et al.[35] further suggest, in combination with the results of previous 
studies, that distinct risk factors operate in the two ACPA subsets. This diver gence im-
plies that different pathophysiology underlies ACPA-positive and ACPA-negative RA, and 
therefore, that these subsets should be considered as two separate diseases, and studied 
separately in both genetic and functional studies of RA pathophysiology. Previous func-
tional studies have shown that in ACPA-positive RA, immunological responses occur in a 
citrulline-specific manner, and, in mouse models, it has been shown that citrulline-specific 
antibodies can induce and promote arthritis[36, 37]. Furthermore, activation of basophils 
from ACPA-positive patients with RA, in contrast to those from ACPA-negative patients, 
occurs upon expo sure to citrullinated antigens[36]. These find ings thus indicate a differen-
tial response of immune cells to citrullinated antigens. 
Diseases with a distinct pathogenesis might, logically, benefit from different treatment 
strategies. In RA the mainstays of treatment are DMARDs, which are a heterogeneous col-
lection of therapeutic agents for which mechanisms of action are, largely, not well under-
stood. Methotrexate is the most prominent DMARD and is widely used for the treatment of 
RA and other inflam matory diseases. ACPA-positive patients with undifferentiated arthritis 
treated with methotrexate are less likely to progress to RA, and do so at a later time point 
than a placebo control group[38]. By contrast, no effect of methotrexate therapy on pro-
gression to RA could be observed in an ACPA negative patient population, indicating that 
the two ACPA subgroups respond differently to methotrexate treatment[38].
 It is not just methotrexate therapy that produces different outcomes in the two disease 




monoclonal antibody directed towards the B cell marker CD20—has proven to be an ef-
fective therapy. Upon binding of rituximab, circulating B cell populations are depleted for 
periods of at least 3 months. Recently, in a clinical study of rituximab in 208 patients with 
refractory RA, it was shown that the presence of ACPA predicted a better EULAR (Euro-
pean League Against Rheumatism) response at 24 weeks, indicating that this drug might 
have a greater role in the ACPA-positive subset than in ACPA-negative patients[39]. 
Thus, although little is known about the genetic contribution to the development of ACPA-
negative RA, data suggests contrasting genetic backgrounds for the disease subsets char-
acterized by ACPA status. This genetic divergence lends further support that distinct ge-
netic risk factors play a part in specific subsets of the disease. To fully identify the genetic 
risk conferred to RA, genetic risk factors that contribute only to certain disease subgroups 
should be identified. 
In chapter 6, by a candidate gene approach, polymorphisms in the PTGES gene were inves-
tigated for association with RA susceptibility and disease characteristics. The PTGES gene 
is involved in prostaglandin synthesis, a key mediator of inflammation. The prostaglandin 
production is an important target for non-steroid-anti-inflammatory drugs (NSAIDs), which 
are key painkillers in the therapy of RA patients[40, 41]. The initial study in a Swedish RA 
population indicated that no genetic association could be identified in the RA population as 
a whole. However, upon investigation of disease subgroups it seemed that the association 
was mainly conferred to female RA patients. Although this finding could not be replicated 
independently in our Leiden RA population, the minor allele frequencies were biased in the 
same direction. Further replication of this finding is needed to tease apart the exact role 
of the PTGES gene in female RA patients, however, it does indicate that genetic risk fac-
tors might only contribute to a subset of the disease and further investigation into these 
subsets is desirable. 
Linking genotype to biological pathways
The identification of variants that make up the genetic risk conferred to RA is thought to 
provide valuable insight into the pathophysiology that underlies the disease. The next step 
is to translate the genetic associations into biological pathways and use this knowledge for 
the invention of curative therapies for RA. 
As more auto-immune susceptibility loci are being identified, it becomes clear that part of 
these genes overlap between auto-immune diseases. Family based epidemiology studies 
have suggested there is a shared genetic basis underlying auto-immune diseases in gen-
eral, which can explain this overlap[42]. The great number of overlapping genes, however, 
might partly be due to the way genetic association studies are currently performed. In 
both GWAS and candidate gene studies, genetic risk factors are identified by comparing 
patients to healthy individuals. Although this approach is considered best practice, it does 
not distinguish between RA and inflammation in general. Therefore, in functional studies to 
identify the biological relevance of a genetic risk factor this should be taken into account. 





tibility[18]. Interestingly, all identified genes are located within immunological pathways, as 
was expected before hand. However, all the identified genes are possible candidates for 
further functional studies and their relevance in disease pathology is not yet elucidated. It 
should be noted however, that the significantly associated variants are generally named 
after known immune genes that are located in the region. Sometimes only one gene is 
located nearby, making it a reasonable assumption this gene is related to the associated 
variant. Other times, however, the variant might be located in a region harboring several 
genes. An association can also be due to a genetic feature, like a micro-RNA or a regula-
tory element, which has not been described yet. Although this is for a big part due to the 
fact that the actual causative variant has not been identified, studies towards exploring 
the functional consequence of a variant are difficult to perform. Thereby, to translate the 
genetic associations into biological pathways, great hurdles will have to be taken. 
In the candidate gene studies described in this thesis, an attempt to identify the functional 
relevance of the associated genetic variant is made. Although mRNA expression levels 
and serum levels of the associated proteins and genes could be significantly related to the 
genotype, these studies all identified further associations and no functional pathways were 
observed, further indicating that the identification of the disease pathology by translating 
the genetic association into a biological pathway involved in disease remains a difficult 
task to perform.
Concluding remarks
In the current thesis the genetic contribution of non-HLA genes to RA susceptibility was 
further investigated and the functional relevance of these loci was explored. The studies 
described were able to establish several previously identified risk factors in a statistical 
robust manner. Also novel genetic risk factors that are associated with RA susceptibility 
could be identified, as well as risk factors that are conferred to specific subgroups of the 
disease. The next step towards understanding the pathophysiology of RA will be to identify 
the relevance of these risk factors, which might prove to be of great challenge.
references
1. Scott DL, Wolfe F, Huizinga TW Rheumatoid arthritis. Lancet 376; 1094-108.
2. Aho K, Koskenvuo M, Tuominen J, Kaprio J Occurrence of rheumatoid arthritis in a 
nationwide series of twins. J Rheumatol 13; 899-902.
3. MacGregor AJ, Snieder H, Rigby AS et al. Characterizing the quantitative genetic con-
tribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43; 30-7.
4. Silman AJ, MacGregor AJ, Thomson W et al. Twin concordance rates for rheumatoid 
arthritis: results from a nationwide study. Br J Rheumatol 32; 903-7.
5. Gregersen PK, Moriuchi T, Karr RW et al. Polymorphism of HLA-DR beta chains in 
DR4, -7, and -9 haplotypes: implications for the mechanisms of allelic variation. Proc 




6. Gregersen PK, Shen M, Song QL et al. Molecular diversity of HLA-DR4 haplotypes. 
Proc Natl Acad Sci U S A 83; 2642-6.
7. Feitsma AL, van der Voort EI, Franken KL et al. Identification of citrullinated vimentin 
peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. 
Arthritis Rheum 62; 117-25.
8. Suzuki A, Yamada R, Chang X et al. Functional haplotypes of PADI4, encoding citrul-
linating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. 
Nat Genet 34; 395-402.
9. Stahl EA, Raychaudhuri S, Remmers EF et al. Genome-wide association study meta-
analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42; 508-14.
10. Barton A, Thomson W, Ke X et al. Re-evaluation of putative rheumatoid arthritis sus-
ceptibility genes in the post-genome wide association study era and hypothesis of a 
key pathway underlying susceptibility. Hum Mol Genet 17; 2274-9.
11. Kobayashi S, Ikari K, Kaneko H et al. Association of STAT4 with susceptibility to rheu-
matoid arthritis and systemic lupus erythematosus in the Japanese population. Arthri-
tis Rheum 58; 1940-6.
12. Remmers EF, Plenge RM, Lee AT et al. STAT4 and the risk of rheumatoid arthritis and 
systemic lupus erythematosus. N Engl J Med 357; 977-86.
13. Barton A, Jury F, Eyre S et al. Haplotype analysis in simplex families and novel analytic 
approaches in a case-control cohort reveal no evidence of association of the CTLA-4 
gene with rheumatoid arthritis. Arthritis Rheum 50; 748-52.
14. Orozco G, Torres B, Nunez-Roldan A, Gonzalez-Escribano MF, Martin J Cytotoxic T-
lymphocyte antigen-4-CT60 polymorphism in rheumatoid arthritis. Tissue Antigens 
64; 667-70.
15. Plenge RM, Padyukov L, Remmers EF et al. Replication of putative candidate-gene 
associations with rheumatoid arthritis in >4,000 samples from North America and 
Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum 
Genet 77; 1044-60.
16. Zhernakova A, Alizadeh BZ, Bevova M et al. Novel association in chromosome 4q27 
region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general 
risk locus for autoimmune diseases. Am J Hum Genet 81; 1284-8.
17. Barton A, Thomson W, Ke X et al. Rheumatoid arthritis susceptibility loci at chromo-
somes 10p15, 12q13 and 22q13. Nat Genet 40; 1156-9.
18. Gregersen PK Susceptibility genes for rheumatoid arthritis - a rapidly expanding har-
vest. Bull NYU Hosp Jt Dis 68; 179-82.
19. Manolio TA, Collins FS, Cox NJ et al. Finding the missing heritability of complex dis-





20. Sica GL, Choi IH, Zhu G et al. B7-H4, a molecule of the B7 family, negatively regulates 
T cell immunity. Immunity 18; 849-61.
21. Yi KH, Chen L Fine tuning the immune response through B7-H3 and B7-H4. Immunol 
Rev 229; 145-51.
22. Azuma T, Zhu G, Xu H et al. Potential role of decoy B7-H4 in the pathogenesis of rheu-
matoid arthritis: a mouse model informed by clinical data. PLoS Med 6; e1000166.
23. Hinks A, Barton A, Shephard N et al. Identification of a novel susceptibility locus for 
juvenile idiopathic arthritis by genome-wide association analysis. Arthritis Rheum 60; 
258-63.
24. Botto M, Walport MJ C1q, autoimmunity and apoptosis. Immunobiology 205; 395-406.
25. Konttinen YT, Ceponis A, Meri S et al. Complement in acute and chronic arthritides: 
assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis 
55; 888-94.
26. Wouters D, Voskuyl AE, Molenaar ET, Dijkmans BA, Hack CE Evaluation of classi-
cal complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 
complexes as novel activation products. Arthritis Rheum 54; 1143-50.
27. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an 
American College of Rheumatology/European League Against Rheumatism collabora-
tive initiative. Ann Rheum Dis 69; 1580-8.
28. Syversen SW, Gaarder PI, Goll GL et al. High anti-cyclic citrullinated peptide levels and 
an algorithm of four variables predict radiographic progression in patients with rheu-
matoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 67; 212-7.
29. van der Woude D, Young A, Jayakumar K et al. Prevalence of and predictive factors for 
sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthri-
tis: results from two large early arthritis cohorts. Arthritis Rheum 60; 2262-71.
30. Huizinga TW, Amos CI, van der Helm-van Mil AH et al. Refining the complex rheu-
matoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for 
antibodies to citrullinated proteins. Arthritis Rheum 52; 3433-8.
31. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH et al. Association of HLA-DR3 
with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis 
Rheum 52; 3058-62.
32. Stahl EA, Raychaudhuri S, Remmers EF et al. Genome-wide association study meta-
analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42; 508-14.
33. Lorentzen JC, Flornes L, Eklow C et al. Association of arthritis with a gene complex 
encoding C-type lectin-like receptors. Arthritis Rheum 56; 2620-32.
34. Sigurdsson S, Padyukov L, Kurreeman FA et al. Association of a haplotype in the 
promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. 




35. Padyukov L, Seielstad M, Ong RT et al. A genome-wide association study suggests 
contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. 
Ann Rheum Dis 70; 259-65.
36. Schuerwegh AJ, Ioan-Facsinay A, Dorjee AL et al. Evidence for a functional role of IgE 
anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci U S A 
107; 2586-91.
37. Uysal H, Bockermann R, Nandakumar KS et al. Structure and pathogenicity of anti-
bodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 
206; 449-62.
38. van DH, van AJ, Lard LR et al. Efficacy of methotrexate treatment in patients with 
probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. 
Arthritis Rheum 56; 1424-32.
39. Sellam J, Hendel-Chavez H, Rouanet S et al. B-cell activation biomarkers as predictive 
factors of the response to rituximab in rheumatoid arthritis. Arthritis Rheum.
40. Halushka MK, Halushka PV Toward individualized analgesic therapy: functional cyclo-
oxygenase 1 and 2 haplotypes. Clin Pharmacol Ther 79; 404-6.
41. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B Identification of human pros-
taglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, con-
stituting a potential novel drug target. Proc Natl Acad Sci U S A 96; 7220-5.
42. Hemminki K, Li X, Sundquist K, Sundquist J Shared familial aggregation of susceptibil-
ity to autoimmune diseases. Arthritis Rheum 60; 2845-7.
43. Kurreeman FA, Padyukov L, Marques RB et al. A candidate gene approach identifies 













Reumatoïde artritis (RA) is een veel voorkomende auto-immuun aandoening waarbij een 
chronische ontsteking van de gewrichten een centrale rol speelt. Ondanks een nog gro-
tendeels onbekende etiologie, is het bekend dat zowel genetische- als omgevingsfactoren 
een rol spelen bij het ontstaan van de ziekte. 
In dit proefschrift worden verscheidene studies beschreven, die de rol van genetica binnen 
de etiologie van RA bestuderen. 
Reumatoïde artritis
RA is een auto-immuun aandoening die gekarakteriseerd wordt door een chronische ont-
steking van het synovium, wat kan lijden tot beschadiging van het kraakbeen en subchon-
draal bot met als gevolg misvormingen en invaliditeit. In de westerse wereld is ongeveer 
0,5-1% van de volwassen populatie gediagnosticeerd met deze aandoening. Het komt 
vaker voor bij vrouwen dan bij mannen en de prevalentie neemt toe met de leeftijd. 
Patiënten presenteren zich vaak met gezwollen en pijnlijke gewrichten, waarbij voornameli-
jk de kleine hand- en voetgewrichten zijn aangedaan. Karakteristiek voor een beginnende 
RA is een symmetrische ontsteking van deze gewrichten. 
De belangrijkste pijler binnen de behandeling van RA is de zogenaamde Disease Modifying 
Anti Rheumatic Drugs (DMARDs), wat een heterogene groep van therapeutische middelen 
omvat waarvan het werkingsmechanisme grotendeels onbekend is. Daarnaast speelt de 
groep van biologicals, zoals tumor necrosis factor (TNF) blokkers een belangrijke rol in het 
effectief onderdrukken van de ontsteking. Tegenwoordig kan hierdoor, bij het grootste deel 
van de patiënten, onderdrukking van de chronische ontsteking worden bewerkstelligd met 
als gevolg het beperken van gewrichtsschade en invaliditeit.
Pathofysiologie
Door infiltratie van inflammatoire cellen, zoals macrofagen, T- en B-cellen in het synoviale 
weefsel van RA patiënten vindt een sterke toename van dit weefsel plaats. Ter plaatse van 
de overgang van dit synoviale weefsel naar kraakbeen kan het ontstoken weefsel lokaal 
ingroeien en ontstaat het zogenoemde pannus weefsel, wat schade aan kraakbeen en bot 
en vorming van erosies tot gevolg heeft. Daarnaast zorgt deze chronische ontsteking voor 
een diffuse afbraak van kraakbeen, wat leidt tot gewrichtsspleet versmalling. 
RA wordt algemeen beschouwd als een auto-immuunziekte, gezien de aanwezigheid van 
auto-antilichamen en auto-reactieve T-cellen in zowel het perifere bloed, als in synoviaal 
vocht. Deze anti-lichamen zijn reeds aanwezig in de eerste stadia van de ziekte en kunnen 
enkele jaren voor het ontstaan van de ziekte al worden aangetoond.
Het klassieke auto-antilichaam binnen RA is reuma factor (RF). Dit antilichaam bindt aan 
het Fc gedeelte van immuunglobuline G, waarbij het een belangrijke rol speelt in comple-
ment activatie en interactie met Fc receptoren. De precieze rol van RF binnen de pathofysi-
ologie van RA is nog grotendeels onbekend. De sensitiviteit varieert tussen de 60 en 70% 





Een ander belangrijk auto-antilichaam binnen RA is Anti Citrullinated Peptide Antibody 
(ACPA) wat gericht is tegen gecitrullineerde eiwitten. Deze eiwitten ontstaan na post-trans-
lationele modificatie van eiwit gebonden arginine.
De rol van deze antilichamen binnen de pathofysiologie van RA is nog grotendeels on-
bekend, maar mogelijk spelen deze antilichamen een belangrijke rol in de etiologie van de 
ziekte. 
Risicofactoren
Bij de ontwikkeling van RA spelen zowel omgevings- als genetische factoren een belan-
grijke rol. Uit studies is gebleken dat ongeveer 50% toebedeeld kan worden aan erfelijke 
factoren, waarvan het human leukocyte antigen (HLA) locus het belangrijkste is. Als gevolg 
van nieuwe genotyperingstechnieken is de identificatie van genetische risicofactoren die 
geassocieerd zijn met de ziekte de afgelopen jaren in een sneltreinvaart verlopen. Momen-
teel zijn ruim honderd genetische variaties geïdentificeerd die associëren met het hebben RA.
In dit proefschrift onderzochten we de contributie van verschillende genetische varianten 
die buiten het HLA locus zijn gelegen. 
Genetische risicofactoren
Replicatiestudies
Nadat aangetoond is dat een bepaalde genetische variatie associeert met het hebben van 
RA, is het van belang deze associatie ook in andere cohorten te onderzoeken en zo de vals 
positieve bevindingen te identificeren. In zowel hoofdstuk twee als drie worden twee van 
deze replicatiestudies beschreven. In hoofdstuk twee worden drie, eerder geïdentificeerde 
genetische variaties, respectievelijk STAT4, CTLA4 en IL2/IL21, onderzocht op associatie 
binnen een Nederlands cohort van RA patiënten. Voor alle drie de varianten kon een as-
sociatie worden aangetoond zowel in het Nederlandse cohort, als in een meta-analyse van 
alle tot dan toe gepubliceerde studies. Binnen de gedachte dat ACPA positieve RA mo-
gelijk een andere pathofysiologie kent dan ACPA negatieve RA, is ook onderzocht of deze 
varianten verschillend associeerden binnen deze twee patiënten groepen. Gezien het feit 
dat er onvoldoende data beschikbaar was voor een gedegen uitspraak over de associatie met 
IL2/IL21 is dit locus hiervoor buiten beschouwing gelaten. Wel kon worden aangetoond dat 
de associatie van CTLA4 met name lijkt bij te dragen in de ACPA positieve patiëntengroep, 
in tegenstelling tot STAT4, die in beide patiëntengroepen associeert met het hebben van RA.
In hoofdstuk drie werd een andere replicatie studie uitgevoerd, waarbij onderzocht werd 
of twee genetische varianten, gelegen in de IL2RA en IL2RB loci, geassocieerd waren 
met RA in een Nederlands cohort. Voor beide variaties kon deze associatie worden aan-
getoond, een aanwijzing dat de IL2 pathway een rol speelt in de pathofysiologie van RA.
Interactie
Een bepaalde genetische variatie gelegen in het HLA locus, de zogenaamde shared epi-
tope (SE) allelen, komen vaker voor bij patiënten met RA in vergelijk met gezonde con-




nog steeds de belangrijkste erfelijke component. Het is bekend dat binnen een Noord-
Amerikaanse inheemse bevolkingsgroep uit centraal Canada deze SE allelen frequenter 
voorkomen, waarbij binnen deze groep ook een hogere prevalentie van RA bestaat. In 
hoofdstuk vier is onderzocht of het hebben van deze SE allelen in combinatie met een van 
de andere, tot dan toe bekende, associërende genetische variaties een hogere kans gaf 
op het hebben van RA. Hierbij is gezien dat de aanwezigheid van HLA-DRB1 in combinatie 
met de genetische variatie gelegen in het C5-TRAF locus, sterker associeerde met het heb-
ben van RA dan beide genetische variaties apart van elkaar. De reeds bekende associatie 
met MMEL-1 liet echter een verminderde associatie met RA zien binnen de HLA-DRB1 
positieve patiënten groep. Deze studie toont hiermee een modulerend effect van de genen, 
gelegen buiten het HLA gebied, aan.
Kandidaat gen studies
Naast het onderzoeken van de reeds bekende associërende genetische variaties is het 
van groot belang om nieuwe associaties te ontdekken. Dit kan gedaan worden door uit-
gebreide, niet hypothese gedreven, studies uit te voeren, waarbij genen gelegen over het 
gehele genoom worden getest in grote patiënt cohorten. Nadelig hiervan zijn de hoge 
kosten die dit met zich meebrengt, met name in de eerste dagen van introductie van deze 
nieuwe technieken. Een andere benadering is om hypothese gedreven een specifiek gen 
van interesse te onderzoeken. In hoofdstuk vijf is op laatstgenoemde wijze een kandidaat 
gen onderzoek gedaan naar genetische variaties gelegen op het VTCN1 locus. Uit eerder 
onderzoek was gebleken dat VTCN1, wat codeert voor B7-H4, een negatieve regulator 
van T-cel activiteit, associeert met juveniele idiopathische artritis. Kort voor start van het 
onderzoek was een studie gepubliceerd, waarin werd beschreven dat hoge levels B7-H4 
frequenter werden waargenomen in RA patiënten dan in gezonde controles en dat dit 
geassocieerd was met een hogere ziekte activiteit. In dit hoofdstuk werd een significante 
associatie aangetoond met het hebben van RA in vergelijk met gezonde controles in een 
Nederlands cohort. Replicatie van onze bevindingen in twee Scandinavische cohorten liet 
een vergelijkbare associatie zien. Na een stratificatie voor ACPA status, kon worden aan-
getoond dat deze genetische associatie met name was toe te schrijven aan een associatie 
van VTCN1 met de ACPA negatieve groep van RA. 
In hoofdstuk zes wordt een andere kandidaat gen studie besproken, waarbij de associatie 
van het prostaglandine E synthase (PTGES) gen met RA werd onderzocht. PTGES codeert 
voor microsomaal prostaglandine E2, wat een belangrijke rol speelt bij ontsteking. In zowel 
een Zweeds als een Nederlands cohort is gekeken naar de associatie van verschillende 
genetische variaties met RA. Hierbij werd in het Zweedse cohort gevonden dat een bepaal-
de genetische variatie vaker voorkwam bij vrouwen met RA, dan bij gezonde vrouwelijke 
controles. In een meta-analyse, waarbij het Nederlandse cohort werd geïncludeerd, kon 
deze associatie ook worden aangetoond. Tenslotte werd gezien dat het genotype dat as-
socieerde met een hogere DAS28, een maat voor de ziekte activiteit, een hogere expressie 
van mPGES-1 in synoviaal weefsel gaf. Deze bevindingen laten zien dat dit gen mogelijk 





In hoofdstuk zeven wordt een studie beschreven waar de genetische associatie tussen 
het C1q gen en RA wordt onderzocht. Uit eerdere studies was gebleken dat complement 
mogelijk een rol speelt in RA. Zo zijn in het synovium van RA patienten complement de-
posities gevonden en bestaat een correlatie tussen ziekte activiteit en de aanwezigheid van 
aan C1q gebonden, geactiveerde complement fragmenten. 
In de studie in hoofdstuk zeven zijn meerdere genetische variaties bepaald in een Neder-
lands cohort van RA patiënten en gezonde controles en bleek een van de geteste variaties 
te associëren met het hebben van RA. Deze genetische variatie is vervolgens in verschil-
lende andere cohorten en in een meta-analyse onderzocht, waarbij deze bevinding werd 
gerepliceerd. Tevens werd gevonden dat deze genetische variatie gecorreleerd is aan C1q 
levels in gezonde controles, wat impliceert dat deze variatie van invloed is op de C1q 
productie. 
Het complementsysteem
Zoals boven genoemd spelen auto-antilichamen een belangrijke rol in de pathofysiologie 
van RA. Gezien in hoofdstuk zeven een aanwijzing is gevonden dat C1q mogelijk een rol 
speelt in de pathofysiologie van RA en de associërende genetische variatie van invloed 
is op de productie van C1q, is het in het laatste hoofdstuk, hoofdstuk acht, een studie 
ingevoegd waarin de bestaande literatuur over complement activatie door (auto-)antilicha-
men op een rij is gezet. Hierin wordt een overzicht gegeven van de huidige kennis op dit 
gebied en wordt beschreven dat complement activatie via de drie verschillende pathways 
van activatie kan verlopen en niet alleen, zoals bekend, via de klassieke route middels C1q 
binding aan de Fc regio’s van IgG en IgM. 
Conclusie
In het huidige proefschrift is de bijdrage van genetische variaties gelegen in non-HLA ge-
nen onderzocht op hun rol in de pathofysiologie van RA. In de beschreven studies is een 
aantal eerder geïdentificeerde risicofactoren verder onderzocht en kon op deze wijze een 
statisch robuuste onderbouwing worden geleverd voor de associatie met RA. Ook zijn 
nieuwe genetische risicofactoren beschreven, waarbij enkele specifiek geassocieerd zijn 
met subgroepen van de ziekte. In navolging van de beschreven studies zal onderzocht 
moeten worden wat de betekenis van de beschreven genetische variaties is voor het ont-
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